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SUMMARY 
Breast cancer is the leading cause for cancer deaths among females worldwide and its 
incidence is growing. The high rate of relapse and metastatic spread is attributed to breast 
cancer stem cells (CSCs) (1). Of note, CSC formation is closely linked to epithelial-
mesenchymal transition (EMT), a process which confers mesenchymal properties on 
epithelial cells (2). Hence, the pharmacological targeting of EMT may represent a new 
strategy to overcome tumor progression. Recent reports showed that targeting the 
endolysosomal machinery is a promising approach to overcome EMT (3). To this end, the 
vacuolar H
+
-ATPase (V-ATPase) represents an attractive target. V-ATPases are ubiquitous 
expressed, multimeric ATP-dependent proton pumps, essential for ligand internalization, 
endosomal recycling and lysosomal degradation (4). Although V-ATPase has been linked with 
the recycling of E-cadherin, a crucial player in EMT, detailed information about a potential 
role of V-ATPase in EMT and CSCs is still missing. 
In fact, we introduce V-ATPase as a promising target affecting EMT and breast CSC formation. 
By using Archazolid A, a myxobacteria-derived V-ATPase inhibitor, we show that V-ATPase is 
pharmacologically accessible. The approach to mimic EMT was accomplished by utilizing a 
mammary cell line model, designed to undergo EMT, namely human mammary epithelial 
(HMLE) cells. In this study, pharmacological and genetic V-ATPase inhibition during EMT 
revealed a distinct implication on the generation of breast CSCs. In fact, Archazolid A 
decreased mammosphere formation of HMLE cells sustainably. Investigating the underlying 
mechanism showed that V-ATPase inhibition abrogates E-cadherin internalization and 
degradation by disturbed delivery from early endosomal to lysosomal compartments (Figure 
1). Moreover, pharmacological V-ATPase inhibition overcame enhanced migration and breast 
CSC formation of mesenchymal HMLE cells, which have already undergone EMT. 
In summary, this work outlines the pivotal role of targeting EMT by interfering with the 
endolysosomal recycling and degradation of E-cadherin and provides pioneer insights into  
V-ATPase inhibition-related repression of cancer stem-like characteristics.  
In conclusion, this work suggests V-ATPase inhibition by Archazolid A as a potent new 
strategy for the treatment of premetastatic and metastatic breast cancer.  
SUMMARY  VII 
 
Figure 1: V-ATPase inhibition impedes EMT-induced migration and mammosphere formation by disrupting  
E-cadherin signaling. (A, B) V-ATPase inhibition blocks E-cadherin internalization (A) and degradation (B) in 
HMLE cells, by disabled translocation of E-cadherin from early endosomes to lysosomes. This leads to impaired 
EMT and thus to the inhibition of migration and mammosphere formation. (C) Archazolid A inhibits migration 
and mammosphere formation of mesenchymal HMLE cells. EE, early endosome; ERC, endocytic recycling 
compartment; LAMP1, lysosomal-associated membrane protein 1; EMT, epithelial-mesenchymal transition; 
MET, mesenchymal-epithelial transition; CSC, cancer stem cell. 
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1 INTRODUCTION 
1.1 Metastatic cancer 
1.1.1 Metastatic breast cancer  
Breast cancer accounts for 25 % of all cancer cases and is the leading cause for cancer-related 
deaths among females worldwide (5). Breast cancer originates from the malignant transition 
of breast epithelial cells, found either lining the milk ducts or in the milk-producing lobules of 
the breast. While it is highly treatable during primary stages, approximately 30 to 50 % of 
patients diagnosed with breast cancer will subsequently develop metastasis, which is 
accompanied with poor prognosis. Breast cancer tumors are heterogeneous in each 
individual patient and comprise subpopulations of cancer cells with extremely high 
tumorigenic potential, termed breast cancer stem cells (bCSCs) (1, 6). Besides enhanced 
resistance to chemo- and radiotherapy, bCSCs have also shown to induce metastasis (7, 8). 
These are major problems which limit therapeutic success of breast cancer treatment and 
result in reduced overall survival. 
1.1.2 Cancer stem cells 
In the vivid debate about the causes for drug resistance and tumor progression, two major 
theories are discussed. The clonal evolution model proposes that all tumor cells possess 
equal tumorigenic potential (9). However, the discovery of cancer stem cells (CSCs) in solid 
tumors assumes a hierarchical organization, by which only a small subpopulation of 
neoplastic cells within the tumor acquire stem cell-like properties. In this current model, only 
CSCs are supposed to drive tumorigenesis and cause relapse (10). In detail, CSCs are cancer 
cells possessing characteristics associated with multipotent stem cells (SC), including 
resistance to apoptosis and most importantly self-renewal. However, the development of the 
initial CSC, namely the tumor-initiating cell (TICs), is poorly characterized. During recent years 
several hypothesis have emerged. Amongst others, TICs are suggested to originate from 
adult stem or progenitor cells by malignant mutations (10, 11). Moreover, in 2008, Weinberg 
and colleagues revealed that CSC-like phenotype and properties can also evolve from 
mature, differentiated epithelial cells (Figure 2) (2). In line, recent reports showed that  
INTRODUCTION   3 
self-renewal and invasiveness are closely associated with traits of cells undergoing epithelial-
mesenchymal transition (EMT), a process which enables cancer cells to disseminate from 
primary tumors (12-14). Indeed, induction of EMT in immortalized human mammary 
epithelial (HMLE) cells exhibits increased expression of cancer stem-like markers and 
characteristics (2, 15).  
 
Figure 2: Theories about the origin of tumor-initiating stem cells (TIC). One theory assumes that TICs arise 
from malignant mutations of adult stem or progenitor cells. A further theory states that they develop from 
normal cells within epithelial tissues by mutations or spontaneous EMT, mediated by microenvironmental 
factors. Hereby, cells uncommonly acquire the feature of self-renewal. TICs form a heterogeneous epithelial 
tumor, comprising cells with limited replicative potential. Adapted from Martin-Belmonte et al. (16). 
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1.2 Epithelial-mesenchymal transition – A hallmark of cancer 
1.2.1 Epithelial-mesenchymal transition 
Epithelial-mesenchymal transition (EMT) describes a pivotal biological process by which 
epithelial cells lose their epithelial characteristics and gain mesenchymal properties. The loss 
of cell-cell adhesion and apical cell polarity results in complex changes in cell architecture 
and behavior. These are characterized by enhanced motility, elevated resistance to apoptosis 
and increased production of extra cellular matrix (ECM) components. Degradation of the 
basement membrane enables migration and invasion of cells into the vasculature. Multiple 
signaling molecules mediate EMT, including TGF-β, Wnt/β-catenin, Notch and Hedgehog 
signaling by activation of EMT transcription factors like Twist1, Twist2, Snail2, Slug, ZEB1 and 
ZEB2. Some of the underlying signaling mechanisms are not fully revealed and still under 
investigation. Subsequent to EMT induction, expression of specific cell-surface proteins, 
reorganization and expression of cytoskeletal proteins, production of ECM-degrading 
enzymes and changes in the expression of specific microRNAs are induced. Several factors 
which are involved in the EMT process, including surface proteins (e.g. E- and N-cadherin), 
intermediate filament protein (e.g. vimentin) as well as transcription factors are often used 
as biomarkers to demonstrate the passage of a cell through EMT (Figure 3). One important 
transcription factor is Twist1. It is a highly conserved basic helix-loop-helix (bHLH) protein 
that plays an important role in embryogenesis and tumorigenesis. In terms of cancer, Twist1 
is able to transform non-tumorigenic HMLE cells into stem-like cells via EMT (2). The reverse 
process of EMT is described by the mesenchymal-epithelial transition (MET), which involves 
the conversion of mesenchymal cells to epithelial cells (17, 18). EMT comprises a central role 
in the formation of many tissues and organs, in the development of the embryo as well as in 
pathological fibrosis. Importantly, as mentioned above, it also plays a pivotal role in CSC 
formation and therefore in cancer progression. 
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Figure 3: Epithelial-mesenchymal transition (EMT). EMT confers mesenchymal properties on epithelial cells. 
Hereby, epithelial cells lose their polarity, detach from the basement membrane and enter the circulation. The 
transition involves changes of several biomarkers. ZO-1, zona occludens-1; MUC1, mucin 1; miR200, microRNA 
200. Adapted from Qiagen, 2012. 
1.2.2 EMT in physiological and pathological events 
1.2.2.1 EMT in embryogenesis and tissue organ development – type I 
Developmental EMT is associated with implantation and genesis of the embryo as well as 
organ formation. Precursors of the cytotrophoblast cells, the trophectoderm, undergo EMT, 
thereby facilitating the invasion of the endometrium and the subsequent proper placenta 
placement, thus enabling nutrient and gas exchange to the embryo. Organ formation 
requires the remodeling of a simple epithelium layer to a multilayer by delamination and 
invagination. EMT facilitates the conversion of epithelial into mesenchymal cells to form 
these layers by gastrulation (18).  
1.2.2.2 EMT in fibrosis and tissue regeneration – type II 
The repair-associated EMT is initiated following inflammation or trauma. Organ fibrosis is 
mediated by inflammatory cells and fibroblasts and occurs in a number of epithelial tissues, 
including kidney, liver, lung and intestine. However, once inflammation is attenuated, EMT 
ceases, as seen during tissue regeneration and wound healing. In the latter, keratinocytes at 
the border of the wound first undergo EMT and subsequently reepithelialization when the 
wound is closed (18). 
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1.2.2.3 EMT in cancer progression and metastasis – type III 
In cancer biology, cells acquire the ability to migrate, invade and metastasize upon EMT 
induction. In detail, during the process of metastasis, cancer cells disseminate from a primary 
tumor, initiated by the loss of cell-cell contacts. Hereby, cells enter the bloodstream and 
reach distant sites, where they undergo MET and form secondary tumors (18). Malignant 
neoplasms at secondary sites are attributed to the ability of cancer cells to self-renew and 
thus gain CSC-like traits. Evidence shows, that epithelial cells, which have undergone EMT, 
display CSC-like characteristics, indicating a crosstalk between EMT and pathways involved in 
regulating stemness in cancer (2).  
1.2.3 Regulation of EMT 
1.2.3.1 EMT induction 
The EMT program can be initiated by multiple extracellular inducers, including TGF-β,  
c-Met/HGF, hypoxia, Wnt and Notch signaling. Hereby, transcription factors are activated, 
which mediate EMT-inducing target gene expression. 
One prominent EMT inducer is the cytokine TGF-β. It regulates cell proliferation, 
differentiation, apoptosis and development during embryogenesis (19). Postnatally, TGF-β 
facilitates EMT in wound healing, immune system and fibrosis. However, in terms of cancer, 
TGF-β comprises a dual role. It is released by blood platelets and stromal cells and prevents 
in most cases malignant transformation and tumor progression, by regulating cellular 
proliferation, differentiation, survival and adhesion. However, cancer cells may gain the 
ability to avoid suppressive influence of TGF-β. In turn, TGF-β alters its function and mediates 
tumor growth and immune surveillance (20). Moreover, TGF-β is also known to induce cancer 
cell invasion and dissemination by inducing EMT (21). Mechanistically, in mammary epithelial 
cells, TGF-β receptors are localized at tight junctions, which interact with two important 
regulators of cell polarity: Par6 and Occludin. Upon TGF-β stimulation, TGF-β-type II receptor 
phosphorylates these regulators. This leads to the loss of tight junctions and thereby to a 
morphological change of the cells from a cuboidal to an elongated spindle-like shape. 
However, TGF-β is also suggested to interact with Wnt, Notch and receptor tyrosine kinase 
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pathways, all of which lead to the loss of epithelial markers such as E-cadherin and gain of 
mesenchymal markers, including fibronectin and vimentin (22).  
Furthermore, Notch1 signaling activation at least partly mediates EMT and is closely 
associated with the genesis of CSCs. Hereby, the Notch intracellular domain (NICD) is cleaved 
off the transmembrane Notch1 receptor by the γ-secretase. NICD translocates into the 
nucleus, inducing a mesenchymal phenotype and thus enhances tumorigenesis (23).  
1.2.3.2 The major player in EMT: E-cadherin 
A key hallmark of EMT is the change of cell surface proteins, most notably the replacement of 
the transmembrane calcium-dependent glycoprotein E-cadherin into neural-cadherin  
(N-cadherin). E-cadherin is a classical type I cadherin, consisting of five extracellular  
Ca
2+
-binding domains (EC1-EC5) which establish homophilic interactions with adjacent  
E-cadherin molecules (Figure 4). These interactions are essential for the formation of 
adherens junctions in order to link epithelial cells to a functional monolayer (24-26).  
The cytoplasmic domain of E-cadherin interacts with three catenins: β-catenin, α-catenin  
and p120, which link E-cadherin to the actin cytoskeleton in order to facilitate cell  
integrity.  
 
Figure 4: E-cadherin mediated adherens junction. E-cadherin is a transmembrane protein, comprising five  
Ca
2+
-binding repeats (EC1-EC5) in the extracellular domain, one transmembrane domain and one intracellular 
domain which is associated with catenins (β-catenin, α-catenin and p120). This complex tethers E-cadherin to 
the F-actin cytoskeleton, forming stable adherens junctions between neighboring cells. EC, E-cadherin domains; 
F-actin, filamentous-actin. 
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The internalization of E-cadherin from cell surface into early endosomes, as well as recycling 
and trafficking to the lysosomes is a dynamic process and crucial to ensure the formation of 
adherens junctions and thus cell adhesion (27, 28).  
Upon EMT induction, the loss of E-cadherin is regulated by multiple transcription factors: 
Either directly by binding of transcription factors such as Snail1/2, ZEB1/2, and Slug or 
indirectly by binding of Twist1 to the E-cadherin promoter containing an E-box element, 
which is responsible for its transcriptional repression (29-34). Thereby, multiple pathways are 
activated to induce the expression of mesenchymal proteins such as N-cadherin, vimentin 
and fibronectin. Thus, the interaction of cells with extracellular matrix proteins and cell 
migration is enabled.  
Endosomal internalization and recycling or lysosomal degradation of receptors and surface 
proteins are crucial processes for the maintenance of cell homeostasis, as shown for example 
for the transferrin/transferrin-receptor recycling (35). As mentioned before, E-cadherin 
recycling and degradation is mediated by the endolysosomal machinery, which is in turn 
dependent on a functioning acidification of the endolysosomal system. This acidification is 
facilitated by proton pumping vacuolar H
+
-ATPases (V-ATPases) (3). Lysosomal degradation is 
enabled by the activated tyrosine kinases c-Met and Src. These kinases mediated 
phosphorylation of E-cadherin, which in turn promotes E-cadherin binding to Hakai E3-ligase. 
Upon Src expression, the GTPases Rab5 and Rab7 are activated, mediating the trafficking of 
E-cadherin/Hakai E3-ligase complex to the LAMP1-positive lysosomes where acidic  
pH-sensitive degrading enzymes mediate E-cadherin degradation (Figure 5) (36).  
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Figure 5: Endolysosomal trafficking of E-cadherin. E-cadherin is internalized from the cell surface and delivered 
to early endosomes. From here, it is either recycled back to the cell membrane or degraded by lysosomes.  
V-ATPase plays a crucial role throughout the trafficking. EE, early endosome; ERC, endocytic recycling 
compartment; TF, transcription factor; EMT, epithelial-mesenchymal transition. 
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1.3 V-ATPase - A potential target for EMT 
1.3.1 Physiological function and structure 
Vacuolar H
+
-ATPases (V-ATPases) are ubiquitous ATP-driven proton pumps, regulating the 
acidification of intracellular compartments, including endosomes, lysosomes, secretory 
vesicles and the Golgi-network (37). Additionally, V-ATPases in the plasma membrane of 
certain cells types, including osteoclasts, renal intercalated cells and epididymal clear cells 
function in processes such as bone resorption, renal acidification or sperm maturation (37, 
38). Interestingly, in recent years, evidence is increasing that V-ATPase also plays a pivotal 
role in cancer cells by mediating an invasive cancer phenotype (39). 
The V-ATPase is a large multi-subunit complex composed of 14 subunits organized into two 
major domains: the cytosolic ATP hydrolysis performing V1 domain and the membrane-
bound V0 domain which transports protons (Figure 6). The V1 domain is composed of eight 
different subunits: A, B, C, D, E, F, G and H. The central hexameric ring consists of three AB 
catalytic heterodimer building sites (A3B3) accomplishing the hydrolysis of ATP to ADP and a 
free phosphate (Pi). The V0 domain consists of six different subunits: a, d, e, c, and c´´, 
whereas yeast additionally contain subunit c´ and higher eukaryotes the accessory protein 
Ac45. The two domains V0 and V1 are connected by peripheral and central stalks (C-H). 
Protons enter subunit a of the V0 domain through a cytoplasmic hemi-channel, thereby 
binding to one of the glutamic acid residues located on each subunit of the c-ring of V0. 
Conformational change of subunit A upon ATP hydrolysis results in the rotation of the central 
stalk of the V-ATPase made up of subunits D and F of V1 and d of V0, consequently causing 
rotation of the c-ring. Thereby, each protonated glutamic acid residue of the c-ring of V0 is in 
close proximity with a luminal hemi-channel in subunit a. Finally, the proton is released into 
the lumen by stabilizing the deprotonated glutamic acid through a subunit a located arginine 
residue (4).  
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Figure 6: Structural model and function of the yeast vacuolar H
+
-ATPase (V-ATPase). The V-ATPase comprises 
two major complexes V1 and V0: The cytosolic V1 domain is made up of eight subunits (A-H) and is involved in 
ATP hydrolysis. The integral V0 domain is located within the membrane and is made up of six subunits (a, d, e, c, 
c´ and c´´) conducting protons (H
+
) across the membrane. Protons can enter the first of the two hemi-channels 
in the subunit a of V0 and bind to a glutamate residue in one of the c-subunits of V0. Upon ATP hydrolysis in the 
A3B3 complex of V1 the conformational change of subunit A causes a central stalk movement of subunits D and F 
of V1 and d of V0. Upon rotation of the c-ring of V0, the proton translocates to the second hemi-channel, 
subsequently releasing it to the lumen. Illustrated according to the model of Forgac et al. (37).  
1.3.2 Role of V-ATPase in cancer and metastasis 
In recent years, many reports have supported the pivotal role of V-ATPase in cancer cells. 
Enhanced V-ATPase expression at the plasma membrane of cancer cells has been found to 
facilitate their invasion by acidifying the microenvironment (40, 41). Low extracellular pH 
accounts for invasiveness in vitro and in vivo in several cancer cells, including prostate, 
hepatocellular, pancreatic and breast cancer (42-47). Furthermore, loss of V-ATPase activity 
showed reduced cell growth and induced apoptosis in cancer cells (48). V-ATPase is also 
associated with drug resistance and its inhibition leads to restored drug sensitivity in cancers, 
such as in non-small-lung cancer (49). Markedly, recent evidence points to a potential role of 
V-ATPase-mediated lysosomal E-cadherin degradation during EMT (3). Nevertheless, a 
detailed study that characterizes the potential function of V-ATPase and the effects of its 
pharmacologic inhibition in CSCs is still missing.  
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1.3.3 The V-ATPase inhibitor: Archazolid A 
Archazolid is a novel, highly specific V-ATPase inhibitor with an IC50 value in the low 
nanomolar range, exerting no effects on F-ATPases or Na
+
/K
+
-ATPases (50, 51). It is a 
myxobacterial secondary metabolite, first isolated from myxobacteria Archangium gephyra 
and Cystobacter violaceus (52). Since 2009, Archazolid A and B are available by chemical total 
synthesis (53). Structurally, Archazolid is composed of a macrocyclic lactone ring with a 
thiazole side chain (Figure 7). It binds within the equatorial region of the V0 rotor subunit c. In 
detail, Archazolid interacts with the essential glutamate within the highly conserved region of 
helix 4 of subunit c, thereby inhibiting the rotation of the c-ring and thus V-ATPase function 
(54). 
 
Figure 7: Chemical structure of Archazolid A. Chemical structure adapted from Huss et al. (50). 
 
In previous years, the work of our group revealed that Archazolid A induces apoptotic cell 
death in cancer cells as well as affects migration in highly metastatic cancer cells (47, 48). 
Lately, anti-leukemic and anoikis resistance abrogating effects have been unveiled (55, 56). 
Moreover, Archazolid was shown to interfere with iron metabolism in breast cancer cells by 
disrupting transferrin receptor internalization, leading to iron deprivation and thus apoptosis 
(35). These promising anti-cancer effects need to be further exploited in order to develop 
potential applications in cancer therapy. So far, investigations on the pharmacological 
accessibility of V-ATPase in terms of CSCs do not exist. 
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1.4 Aim of the study 
What we know so far: 
1. Aggressive breast cancer is attributed to breast cancer stem cells (CSCs) (1, 6). 
2. Breast CSC formation is associated with EMT (2). 
3. V-ATPase plays an important role during EMT (3) and is a promising anti-cancer target 
(42, 47). 
 
We investigated the intruding question:  
Is the pharmacologically accessible V-ATPase a new target to abrogate EMT and CSC 
formation?  
 
Figure 8: Investigation of the link between V-ATPase, EMT and CSC formation.  
 
 
 
 
The aim of this study was to examine the effects of V-ATPase inhibition during EMT on bCSC 
formation, thereby investigating the major hallmarks of metastasis: tumor cell migration and 
cancer stem cell-induced mammosphere formation. In addition, the underlying cellular 
mechanism of V-ATPase inhibition during EMT was investigated. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Compound 
Archazolid A was generously provided by Dr. Rolf Müller (Helmholtz Centre for Infection 
Research, Saarbrücken).  
2.1.2 Reagents and technical equipment 
Table 1: Biochemicals, kits, dyes and cell culture reagents 
Reagent Producer 
4-hydroxytamoxifen Sigma-Aldrich, Taufkirchen, Germany 
B27® Supplement (50x) Gibco, Life Technologies, Carlsbad, USA 
bFGF Peprotech, Rocky Hill, USA 
Blasticidin Gibco, Germering, Germany 
Bovine serum albumin   Sigma-Aldrich, Taufkirchen, Germany 
Bradford Reagent
TM
 Bio-Rad, Munich, Germany 
Complete® EDTA free Roche Diagnostics, Penzberg, Germany 
Crystal violet Carl Roth, Karlsruhe, Germany 
DMSO Sigma-Aldrich, Taufkirchen, Germany 
EDTA Carl Roth, Karlsruhe, Germany 
EGTA Sigma-Aldrich, Taufkirchen, Germany 
EGF Peprotech, Rocky Hill, USA 
EMT Antibody Sampler Kit  Cell Signalling Technology, Cambridge, UK 
FCS Biochrom AG, Berlin, Germany 
FluorSave
TM
 Reagent Merck, Darmstadt, Germany 
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems, Foster City, CA, USA 
Hoechst 33342 Sigma-Aldrich, Taufkirchen, Germany 
IPTG Sigma-Aldrich, Taufkirchen, Germany 
LysoTracker® dye Moleculare Probes, Darmstadt, Germany 
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MECGM, ready-to-use PromoCell GmbH, Heidelberg, Germany 
MEGM
TM
 Bullet Kit Lonza, Basel, Switzerland 
Methylcellulose Sigma-Aldrich, Taufkirchen, Germany 
Na3VO4 ICN Biomedicals, Aurora, Ohio, USA 
NaCl Sigma-Aldrich, Taufkirchen, Germany 
NaF Merck, Darmstadt, Germany 
Non-fat dry milk powder (Blotto) Carl Roth, Karlsruhe, Germany 
Page-Ruler 
TM
 Prestained Protein Ladder Fermentas, St. Leon-Rot, Germany 
Penicillin/Streptomycin PAA Laboratories, Pasching, Austria 
PFA Sigma-Aldrich, Taufkirchen, Germany 
PMSF Sigma Aldrich, Munich, Germany 
Polyacrylamid Carl Roth, Karlsruhe, Germany 
Poly-HEMA Sigma-Aldrich, Taufkirchen, Germany 
PowerUp 
TM
 SYBR Green Master Mix  Applied Biosystems, Foster City, CA, USA 
Propidium iodide Sigma-Aldrich, Taufkirchen, Germany 
Puromycin Dihydrochloride  Sigma-Aldrich, Taufkirchen, Germany 
Qiagen RNeasy Mini Kit Qiagen, Hilden, Germany 
RPMI 1640 PAN Biotech, Aidenbach, Gemrany 
shRNA MISSION Lentiviral Transduction Particles  Sigma-Aldrich, Taufkirchen, Germany 
Taqman Master Mix  Life Technologies Corporation, Carlsbad, 
USA 
TCE Sigma-Aldrich, Taufkirchen, Germany 
TGF-β Peprotech, Rocky Hill, USA 
TNS PromoCell GmbH, Heidelberg, Germany 
Trisodium citrate dicydrate Sigma-Aldrich, Taufkirchen, Germany 
Triton X-100 Merck, Darmstadt, Germany 
Trypsin PAN Biotech, Aidenbach, Germany 
Tween 20 Bio-Rad, Munich, Germany 
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Table 2: Commonly used solutions and media 
PBS (pH 7.4)   PBS + Ca
2+
/Mg
2+
 (pH 7.4)   
NaCl 132.2 mM NaCl 137 mM 
Na2HPO4 10.4 mM KCl 2.68 mM 
KH2PO4 3.2 mM Na2HPO4 8.10 mM 
in H2O   KH2PO4 1.47 mM 
 
MgCl2 0.25 mM 
in H2O   
Mammary epithelial cell growth medium 
MECGM 500 ml RPMI   
BPE 2 ml RPMI 1640 500 ml 
EGF 5 µg FCS  10 % 
Insulin  2.5 mg non-essential amino acid 1 % 
Hydrocortisone 250 µg Pyruvate 1 % 
P/S 1 % Insulin 10 µg/ml 
DMEM   Trypsin/EDTA (T/E)  
DMEM 500 ml Trypsin 0.5 % 
FCS  10 % EDTA 0.20 % 
P/S 1 % in PBS   
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Table 3: Technical equipment 
 
 
 
 
 
Name Producer 
7300 Real Time-PCR System Applied Biosystems, Foster City, CA, USA 
Axiovert 25/200 microscope Zeiss, Jena, Germany 
Canon EOS 450D camera Canon, Poing, Germany 
ChemiDoc Touch Imaging System  
 
Bio-Rad Laboratories GmbH, Munich, 
Germany 
Consort Electrophoresis Power Supply E835  Sigma-Aldrich, Taufkirchen, Germany 
Curix 60 Agfa, Cologne, Germany 
FACS Calibur Becton Dickinson, Heidelberg, Germany 
ibiTreat μ-slide 8-well ibidi GmbH, Munich, Germany 
Leica-SP8 confocal microscope  Leica Microsystems, Wetzlar, Germany 
NanoDrop® ND-1000 Spectrophotometer Peqlab Biotechnology GmbH, Erlangen, 
Germany 
Nitrocellulose membrane Amersham Bioscience, Freiburg, Germany 
PowerPac HC, Tank Blotting System Bio-Rad, Munich, Germany 
SpectraFluor Plus
TM
 Tecan, Crailsheim, Germany 
Transwell
®
 permeable supports  Corning Incorporated, New York, NY, USA 
Vi-Cell™ XR Beckman Coulter, Krefeld, Germany 
X-ray film (Super RX) Fuji, Düsseldorf, Germany 
Zeiss LSM 510 Meta confocal laser Zeiss, Jena, Germany 
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2.2 Methods 
2.2.1 Cell culture 
Immortalized human mammary epithelial (HMLE) cells, stably transduced with Twist1-ER 
were kindly provided by Dr. Christina Scheel (Helmholtz Centre Munich) and described by 
Casas et al. (32). HMLE cells were cultivated in Mammary Epithelial Cell Growth Medium 
(MECGM, Ready-to-use; PromoCell GmbH, Heidelberg, Germany), supplemented with 
penicillin/streptomycin (P/S; PAA Laboratories, Pasching, Austria) and 10 µg/ml blasticidin 
(Gibco, Germering, Germany). After reaching 80 % confluence, HMLE cells were sub-cultured 
(1:5-1:10) in 75 cm
2
 culture flasks, or seeded either in multiwell-plates or ibidi µ-slides (ibidi 
GmbH, Munich, Germany) for respective experiments. Cells were washed once with 
prewarmed PBS and 1 ml Trypsin/EDTA (T/E) was added for 15-20 min at 37 °C. The 
detachment of the cells was stopped with Trypsin Neutralizing Solution (TNS; PromoCell 
GmbH, Heidelberg, Germany). Cells were plated after adjustment of the cell concentration 
with Vi-Cell™ XR (Beckman Coulter, Krefeld, Germany).  
Highly invasive MDA-MB-231 cells were purchased from Cell Line Services (Eppelheim, 
Germany), cultivated in DMEM and passaged twice a week (1:10). The MCF-7 breast cancer 
cell line (ACC 115, DSMZ, Braunschweig, Germany) was cultured in RPMI and passaged twice 
a week (1:10). All cell lines were cultured under constant humidity at 37 °C and with 5 % CO2.  
2.2.2 Freezing and thawing 
For freezing nitrogen stocks, HMLE cells with 80 % confluence were washed with PBS, 
trypsinized and centrifuged (1.000 rpm, 5 min at room temperature (RT)). 1 x 10
6 
cells were 
resuspended in 1 ml freezing medium and transferred to cryovials. Cells were first frozen at  
-20 °C and then transferred to either -80 °C or to liquid nitrogen (-196 °C) for long-term 
storage.  
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Table 4: Freezing medium HMLE cells 
Freezing medium 
MECGM 70 % 
FCS 20 % 
DMSO 10 % 
 
In order to thaw cells, one cryovial content was immediately dissolved in prewarmed 
MECGM. Subsequently, cells were centrifuged, resuspended in MECGM to remove DMSO 
and seeded in a 25 cm
2
 culture flask. The next day, fresh MECGM was provided for the cells 
and after reaching 70-80 % confluence, cells were transferred to a 75 cm
2 
culture flask. 
2.2.3 Transduction of HMLE Twist1-ER cells with lentiviral V-ATPase shRNA 
For the lentiviral transduction of HMLE Twist1-ER cells with V-ATPase shRNA  
MISSION® Lentiviral Transduction Particles (Vector: pLKO.1-puro-IPTG 3 x LacO;  
SHC332V-1EA; Clone ID: (1) TRCN0000029559, (2) TRCN0000029560 (3) TRCN0000029561, 
(4) TRCN0000029562, (5) TRCN0000029563; Sigma-Aldrich, Taufkirchen, Germany) and 
MISSION® 3 x LacO Inducible Non-Target shRNA Control Transduction Particles (SHC332V, 
Sigma-Aldrich, Taufkirchen, Germany) as a control were used according to the 
manufacturer’s protocol. The pLKO vector contains a Lacl (repressor) and a modified human 
U6 promoter with LacO (operator) sequence, binding to each other. Upon IPTG treatment, 
the allosteric Lacl repressor changes confirmation, releasing itself from LacO modified human 
U6 promoter and subsequently permits expression of the shRNA. HMLE Twist1-ER cells were 
transduced with a multiplicity of infection (MOI) of one. Successfully transduced cells were 
selected by adding 0.5 μg/ml puromycin (Sigma-Aldrich, Taufkirchen, Germany) to the 
medium and puromycin was also added to the medium during cultivation. For sufficient 
shRNA expression, 1 mM IPTG was added for 96 h before experiments were performed. In 
order to ensure sustained V-ATPase downregulation, 1 mM IPTG was constantly added.  
V-ATPase knockdown was examined by PCR analysis. Most efficient knockdown was achieved 
with V-ATPase shRNA clones 1 and 3 which were used for further experiments.  
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2.2.4 V-ATPase inhibition and EMT induction in HMLE Twist1-ER cells and in HMLE  
Twist1-ER shRNA clones 
2.2.4.1 Pharmacological V-ATPase inhibition with Archazolid A and EMT induction in HMLE 
Twist1-ER cells 
Epithelial HMLE Twist1-ER cells were pretreated with 1 or 10 nM Archazolid A for 24 h before 
EMT induction. EMT induction was either mediated by 4-hydroxytamoxifen (4-OH-TX;  
Sigma-Aldrich, Taufkirchen, Germany) or by TGF-β (Peprotech, Rocky Hill, USA). For  
4-OH-TX treatment, fresh MECGM was added with 20 nM for 10 days. 4-OH-TX is an active 
metabolite of tamoxifen and binds to the estrogen receptor (ER). Thereby, the transcription 
factor complex 4-OH-TX/Twist1-ER translocates into the nucleus where it binds to DNA and 
modulates EMT gene expression.  
For TGF-β-mediated EMT induction, 5 ng/ml TGF-β was added to the medium for 12 days. In 
both cases, Archazolid A pretreated cells were stimulated with 0.1 nM Archazolid A for the 
respective EMT duration. Cells were split and supplied with fresh medium and respective 
stimulation reagents every three days.  
Fully transitioned mesenchymal HMLE cells were treated with 1 or 10 nM Archazolid A for 
24 h. 
2.2.4.2 Genetic V-ATPase knockdown and EMT induction in HMLE Twist1-ER shRNA clones 
V-ATPase shRNA clones were pretreated with 1 mM IPTG for 96 h in order to sufficiently 
induce V-ATPase knockdown. EMT induction was either mediated by 4-OH-TX or by TGF-β. 
For 4-OH-TX treatment, fresh MECGM was added with 20 nM 4-OH-TX for 10 days. For TGF-β 
treatment, 5 ng/ml TGF-β was added for 12 days. V-ATPase knockdown was ensured by 
concomitant 1 mM IPTG treatment for the respective EMT duration. Cells were split and 
supplied with fresh medium and respective stimulation reagents every three days.  
2.2.4.3 Induction of Notch1 with EGTA 
MDA-MB-231 and MCF-7 cells were stimulated with 1 or 10 nM Archazolid A for 24 h and 
subsequently treated with 500 nM EGTA for 2.5 h.  
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2.2.5 Immunoblotting 
For protein detection, Western blot analysis was performed. For lysis of the cells, RIPA lysis 
buffer was added and cells were frozen at -80 °C. Protein concentrations of cell lysates were 
determined as described by Bradford (57) using Bradford Reagent
TM
 (Bio-Rad, Munich, 
Germany) and measuring the absorbance with SpectraFluor Plus
TM  
(Tecan, Crailsheim, 
Germany). Equal amounts of proteins were loaded onto sodium dodecyl sulfate (SDS)-gels, 
utilizing Page Ruler
TM
 Prestained as a protein ladder indicator (Fermentas, St. Leon-Rot, 
Germany). Proteins were separated by SDS-polyacrylamide (Carl Roth, Karlsruhe, Germany) 
gel electrophoresis (SDS-PAGE; 20 min: 100 V, 45 min: 200 V) using the Consort 
Electrophoresis Power Supply E835 (Sigma-Aldrich, Taufkirchen, Germany) and transferred to 
nitrocellulose membranes (Amersham Bioscience, Freiburg, Germany) by tank blotting  
(1.5 h: 100 V, 4 °C; Bio-Rad, Munich, Germany). Membranes were blocked with 5 % non-fat 
dry milk powder (Carl Roth, Karlsruhe, Germany) in T-BST for 1 h. Primary antibodies were 
either incubated over night at 4 °C, or for 2 h at RT. Secondary antibodies were incubated for 
2 h at RT. Antibodies were diluted in 5 % BSA (Sigma-Aldrich, Taufkirchen, Germany) in T-BST.  
HRP-coupled secondary antibodies were detected with ECL substrate and 
chemiluminescence was detected with ChemiDoc Touch Imaging System (Bio-Rad 
Laboratories GmbH, Munich, Germany). Quantification of bands was made with Image 
Lab
TM
 Software (Bio-Rad Laboratories GmbH, Munich, Germany). 
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Table 5: Solutions and reagents for Western blot analysis 
RIPA lysis buffer   5x SDS sample buffer   
Tris/HCl (pH 7.4) 50 mM Tris/HCl (pH 6.8) 3.125 M 
NaCl 150 mM Glycerol 50 % 
Nonidet NP-40 1 % SDS 5 % 
Sodium deoxycholate 0.25 % DTT 2 % 
SDS 0.10 % Pyronin Y 0.025 % 
activated Na3VO4 0.3 mM H2O   
NaF 1 mM 
 
β-glycerophosphate 3 mM Stacking gel    
pyrophosphate 10 mM Rotiphorese
TM
 Gel 30 17 % 
H2O    SDS 0.1 % 
added before usage: TEMED 0.2 % 
Complete® EDTA free 4 mM APS 0.1 % 
PMSF 1 mM  H2O  
H2O2 0.5 mM 
  Separation gel 10 %/12 %  
Rotiphorese
TM
 Gel 30 33 %/40 % 
Tris (pH 8.8) 375 mM 
SDS 0.1 % 
TEMED 0.1 % 
APS 0.05 % 
TCE 0.05 % 
   H2O  
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Table 6: Primary antibodies for Western blot analysis * 
Antigen Source Dilution Provider 
Claudin-1 rabbit 1:200 Cell Signalling Technology 
Ductin/c-subunit rabbit 1:500 Merck 
E-cadherin (24E10) rabbit 1:200 Cell Signalling Technology 
Fibronectin (C6F10) mouse 1:500 Santa Cruz Biotechnology 
N-cadherin rabbit 1:200 Cell Signalling Technology 
NICD rabbit 1:1000 Cell Signalling Technology  
Notch1 rabbit 1:500 Cell Signalling Technology  
Vimentin (D21H3) rabbit 1:200 Cell Signalling Technology 
β-catenin (D10A8) rabbit 1:200 Cell Signalling Technology 
Table 7: Secondary antibodies for Western blot analysis * 
Antibody Dilution Provider 
HRP, Goat anti-rabbit IgG (H+L) 1:1000 Bio-Rad 
HRP, Goat anti-mouse IgG 1:1000 Santa Cruz Biotechnology 
* All antibodies were diluted in 5 % BSA and T-BST 
Table 8: T-BST for antibody dilution 
T-BST (pH 8) 
TRIS-Base 30 g 
NaCl 111 g 
Tween 20 20 ml 
H2O ad 1000 ml 
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2.2.6 Quantitative real-time PCR analysis 
Total mRNA was isolated from cell culture samples using Qiagen RNeasy Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s protocol. Messenger RNA (mRNA) 
concentrations were determined using the NanoDrop® ND-1000 spectrophotometer 
(NanoDrop Technologies, Erlangen, Germany). Reverse transcription of mRNA into 
complementary DNA (cDNA) was performed with the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s 
instructions. cDNA was stored at 4 °C until quantitative Real-Time-Polymerase Chain Reaction 
(qRT-PCR) was performed with the ABI 7300 Real Time PCR System (Applied Biosystems, 
Fosterer City, CA, USA). Either TaqMan Universal PCR Mastermix (Life Technologies 
Corporation, Carlsbad, CA, USA) or SYBR Green Master Mix (ThermoFischer Scientific, 
Germering, Germany) were used, respective to the utilized primer. GAPDH (biomers.net, 
Ulm, Germany) or Actin (Applied Biosystems, Foster City, USA) were used as housekeeping 
genes.  
Table 9: Primer for qRT-PCR 
Primer Forward Reverse Method Provider 
E-cadherin 5’CAG CAC GTA CAC AGC CCT 
AA 3’ 
5’ AAG ATA CCG GGG GAC ACT 
CA 3’ 
SYBR Green Metabion 
Vimentin 5’ CGG CGG GAC AGC AGG 3’ 5’ TCG TTG GTT AGC TGG TCC AC 
3’ 
SYBR Green Metabion 
N-cadherin 5’ ACA GTG GCC ACC TAC AAA 
GG 3’ 
5’ CCG AGA TGG GGT TGA TAA 
TG 3’ 
SYBR Green Metabion 
Fibronectin 5’ GCT GAC AGA GAA GAT TCC 
CGA 3’ 
5’ CCA GGG TGA TGC TTG GAG 
AA 3’ 
SYBR Green Metabion 
V-ATPase  5‘ AAC GCT GCG GAG ATC CAG 
A 3‘ 
5‘ GCG ACG ATG AGA CCG TAG 
AG 3‘ 
TaqMan ® Applied 
Biosystems 
GAPDH 5’ ACC ACA GTC CAT GCC ATC 
AC 3’ 
5’ TCC ACC ACC CTG TTG CTG TA 
3’ 
TaqMan ® Biomers.net 
GmbH 
Actin 5‘ TTC ACC TAC AGC AAG GAC 
GA 3‘ 
5’ GAA CTC GAA GAT GGG GTT 
GA 3’ 
SYBR Green Applied 
Biosystems 
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Average CT values of target genes were normalized to control as ΔCT. Changes in mRNA 
expression levels were shown as fold expression (2
-ΔΔ CT
) calculated by the ΔΔCT method (58). 
2.2.7 Immunostaining 
Cells were treated as indicated and seeded into ibidi 8-well µ-slides. For staining, cells were 
washed with PBS
+
 and fixed with 4 % paraformaldehyde (PFA; Sigma-Aldrich, Taufkirchen, 
Germany) for 10 min, washed again with PBS and permeabilized with 0.2 % Triton X-100 
(Merck, Darmstadt, Germany). In order to avoid unspecific binding of the antibody, cells were 
blocked with 0.2 % BSA in PBS (30 min, RT). Primary antibodies were diluted in 0.2 % BSA in 
PBS, incubated overnight at 4 °C and concomitantly washed three times with PBS (3 x 5 min, 
RT). Secondary antibodies were also diluted in 0.2 % BSA in PBS and together with 5 µg/ml 
Hoechst 33342 (Sigma-Aldrich, Taufkirchen, Germany), incubated for 45 min at RT. 
Subsequently, cells were mounted with FluorSave
TM 
Reagent (Merck, Darmstadt, Germany) 
and stored at 4 °C under exclusion of light. Images were obtained using Zeiss LSM 510 Meta 
confocal microscope (Zeiss, Jena, Germany) or Leica-SP8 confocal microscope (Leica 
Microsystems, Wetzlar, Germany).  
Table 10: Primary antibodies for immunostaining 
Antibody Species Dilution Provider 
E-cadherin (24E10) rabbit 1:200 Cell Signalling 
E-cadherin (HECD1) mouse 1:1000 Invitrogen 
LAMP-1 mouse 1:200 Developmental Studies Hybridoma Bank 
N-cadherin (D4R1H) XP rabbit 1:200 Cell Signalling 
Notch1 rabbit 1:400 Cell Signalling 
Rab5 (S-19) rabbit 1:50 Santa Cruz Biotechnology 
Rab7 (D95F2) XP  rabbit 1:100 Cell Signalling 
Vimentin (D21H3) XP  rabbit 1:100 Cell Signalling 
β-catenin (D10A8) XP  rabbit 1:100 Cell Signalling 
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Table 11: Secondary antibodies for immunostaining 
Antibody Dilution Provider 
Alexa Fluor 488 goat anti-rabbit 1:400 Invitrogen 
Alexa Fluor 546 goat anti-mouse  1:400 Invitrogen 
2.2.8 LysoTracker® staining 
Cells were treated as described in figure legends and 25 000 cells/well seeded in 8-well  
µ-slides, stained for 60 min with 100 nM LysoTracker® dye (Moleculare Probes, Darmstadt, 
Germany) and 5 µg/ml Hoechst 33342 in PBS at 37 °C. Stained cells were imaged by confocal 
microscopy (LSM 510 Meta, Zeiss, Oberkochen, Germany) without fixation.  
2.2.9 E-cadherin internalization assay 
HMLE Twist1-ER cells were cultivated, as described, for 10 days. On day 10, cells were seeded 
in ibidi 8-well µ-slides. Cells were washed with ice-cold PBS and slides were kept at 4 °C for 
10 min. In the following, samples were incubated with anti-E-cadherin antibody (HECD1, 
2 µg/ml; Invitrogen, Carlsbad, USA) for 45 min at 4 °C. After three washing steps with PBS, 
prewarmed MECGM medium was added and incubated for indicated time points (0, 5, 10 
and 20 min) at 37 °C. Cells were fixed with 4 % PFA for 15 min at RT and washed with PBS. 
After incubation with the secondary antibody Alexa Flour 488 goat anti-mouse IgG 
(H+L)(1:400) and 5 µg/ml Hoechst 33342 for 30 min at RT, cells were washed three times 
with PBS and mounted with FluorSave
TM 
Reagent and a coverslip. Slides were kept at 4 °C 
with exclusion of light until images were taken, using Leica-SP8 confocal microscope (Leica 
Microsystems, Wetzlar, Germany). 
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2.2.10 Mammosphere assay 
Mammosphere formation assays were performed as described previously by Dontu et al. 
with modifications (59). In brief, cell viability was measured by Vi-CELL
TM
 XR (Beckman 
Coulter, Krefeld, Germany) and 20 000 viable cells/well were resuspended in MEGM medium 
and seeded in ultra-low 12-well attachment plates, coated with poly-(2-hydroxyethyl 
methacrylate) (poly-HEMA). HMLE cells were incubated for 7 days (37 °C, 5 % CO2), allowing 
mammosphere formation in the absence of additional stimulation.  
For secondary mammosphere formation, primary mammospheres were dissociated by T/E 
into single cells and reseeded at 20 000 viable cells/well in poly-HEMA coated plates for  
7 days (37 °C, 5 % CO2). Each well was imaged by LSM 510 Meta confocal microscopy and 
quantity and size of mammospheres were analyzed by using ImageJ.  
Table 12: MEGM mammosphere culture medium 
Mammosphere medium 
MEGM
TM
 Bullet Kit  500 ml 
EGF 20 ng/ml 
bFGF (human) 10 ng/ml 
B-27® Supplements 50 ml 
Methylcellulose 1 % 
2.2.11 Boyden chamber assay 
1 × 10
5 
cells were suspended in MECGM without FCS and added on top of the Transwell
®
 
permeable supports (Corning Incorporated, New York, NY, USA). MECGM (negative control, 
NC) or MECGM with 10 % FCS (Biochrom AG, Berlin, Germany) was added on the bottom of 
the membrane. The Boyden chamber inserts were incubated at 37 °C and 5 % CO2 for 6 h. 
Migrated cells were stained with crystal violet (Carl Roth, Karlsruhe, Germany). Cells on the 
upper side of the insert were removed with cotton swabs. Migrated cells were imaged using 
Zeiss Axiovert25 microscope (Zeiss, Jena, Germany) and Canon EOS 450D camera (Canon, 
Poing, Germany). Cells were counted using the ImageJ plugin cell counter and normalized to 
control.  
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2.2.12 Cell viability assay 
2.2.12.1 Fluorescence activated cell sorting  
Cell viability was measured according to Nicoletti et al. (60), by which the percentage of 
apoptotic nuclei after propidium iodide (PI; Sigma-Aldrich, Taufkirchen, Germany) staining is 
measured. Cells were treated as indicated, washed and harvested. Sub-diploid DNA content 
was determined by permeabilization and staining with hypotonic fluorochrome solution 
(HFS) buffer containing PI (0.1 % (v/v)) over night at 4 °C. Apoptotic cells were measured by 
fluorescence activated cell sorting (FACS) on BD FACS Calibur (Becton Dickinson, Heidelberg, 
Germany), analyzing the respective fluorescence intensity.  
Table 13: HFS buffer with PI 
HFS buffer 
Propidium iodide 75 µM 
Trisodium citrate 0.1 % 
Triton-X 100 0.1 % 
PBS 
2.2.12.2 Cell viability in mammosphere assays 
For mammosphere assays, cell viability was measured by Vi-CELL
TM
 XR (Beckman Coulter, 
Krefeld, Germany) before seeding. 
For visualizing dead cells among mammospheres 50 µg/ml PI (1 h) and for nuclei staining  
5 µg/ml Hoechst 33342 (3 h) were added to the medium and subsequently imaged by LSM 
510 Meta confocal microscopy. 
2.2.13 Statistics 
All experiments were performed at least three times unless otherwise indicated. Statistical 
analysis was accomplished using GraphPad Prism® software version 5.04 (GraphPad 
Software, Inc., La Jolla, CA, USA). Graph data represent means ± SEM. One-way 
ANOVA/Tukey´s Multiple Comparison Test and individual student t-tests were conducted. P 
values less than 0.05 were considered significant. 
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3 RESULTS 
3.1 Characterization of EMT in HMLE Twist1-ER cells 
3.1.1 4-OH-TX induces EMT in HMLE Twist1-ER cells 
In order to mimic EMT in vitro with a well-established model, immortalized HMLE cells 
transduced with Twist1-ER were utilized (2, 32). Upon 4-hydroxytamoxifen (4-OH-TX) 
stimulation, mesenchymal traits were conferred on epithelial cells, by activation and 
expression of the transcription factor Twist1 (Figure 9A). In line with recent reports, 
cuboidal epithelial cells transited into mesenchymal elongated, spindle shaped cells, 
building a dense monolayer (Figure 9B). Furthermore, the expression of the epithelial 
marker E-cadherin was completely reduced and the mesenchymal marker vimentin was 
increased significantly in cells which underwent EMT, as shown by qRT-PCR analysis 
(Figure 9C). These data indicate a gain of mesenchymal traits upon 4-OH-TX treatment.  
 
Figure 9: EMT in HMLE Twist1-ER cells upon 4-OH-TX stimulation. (A) Model for EMT induction in HMLE 
Twist1-ER cells. (B) Morphologic change of HMLE Twist1-ER cells treated with 20 nM 4-OH-TX for 10 days. 
(n=3). (C) mRNA expression of E-cadherin and vimentin in epithelial (epi) and mesenchymal (mes) HMLE 
Twist1-ER cells. (Student´s t-test, *p<0.05, n=3). 
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3.1.2 4-OH-TX induces translocation of Twist1-ER into the nucleus 
Upon 4-OH-TX treatment, the fusion protein between Twist1 and the modified hormone-
binding domain of estrogen receptor (Twist1-ER), is activated and translocates to the 
nucleus, where the transcription factor Twist1 induces EMT. In epithelial cells, Twist1 was 
distributed diffusely, whereas upon 4-OH-TX induction, Twist1 staining was enhanced in 
the nucleus (Figure 10A). This translocation was not modified by Archazolid A treatment. 
In line, mRNA expression of Twist1 after 10 days was upregulated in both, 4-OH-TX and 
Archazolid A treated cells, compared to epithelial cells (Figure 10B). These results show an 
effective Twist1 translocation to the nucleus upon 4-OH-TX treatment and exclude that  
V-ATPase inhibition impairs EMT by interfering with Twist1 translocation. 
 
Figure 10: Twist1 translocation into the nucleus is induced by 4-OH-TX. (A) Twist1 staining (green) of HMLE 
cells without (epithelial, epi) and with 20 nM 4-OH-TX and with/without Archazolid A (Archa A) treatment in 
indicated concentrations is shown. Graph in the upper right panel depicts Twist1 fluorescence signal 
intensity of the nucleus (blue) relative to the entire cell signal (One-way ANOVA, Tukey's Multiple 
Comparison Test, n=3). (B) mRNA expression of Twist1 without and with EMT induction by 20 nM 4-OH-TX 
and with/without Archazolid A treatment in indicated concentrations and time points (12 h, 24 h, 48 h, 72 h, 
96 h, 8 d, 10 d) is shown. (One-way ANOVA, Tukey's Multiple Comparison Test, SEM, ns= not significant, 
n=3).  
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Furthermore, expression of epithelial and mesenchymal markers was analyzed following 
Twist1 activation. Quantitative RT-PCR confirmed the data from Casas et al., revealing 
significant E-cadherin downregulation after 8 days of 4-OH-TX treatment, whereas 
mesenchymal fibronectin and Snail1 were upregulated (Figure 11) (32). Interestingly, 
vimentin expression was enhanced after 48 h, while no difference on the expression 
regarding N-cadherin and Slug was observed over time. Taken together, these results 
confirm published data, suggesting suppression of E-cadherin and therefore EMT 
induction by Twist1 (32). 
 
Figure 11: EMT marker expression over time. mRNA expression of E-cadherin, fibronectin, vimentin,  
N-cadherin, Snail1 and Slug in HMLE Twist1-ER cells for the indicated points: 24 h, 48 h, 72 h, 96 h, 8 d and 
10 d, is shown. (One-way ANOVA, Tukey's Multiple Comparison Test, *p<0.05, n=3). 
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3.2 Role of V-ATPase in HMLE Twist1-ER cells during EMT 
3.2.1 Archazolid A inhibits V-ATPase activity in HMLE Twist1-ER cells during EMT 
Metastatic potential and thus malignancy of cancer cells often correlates with either 
enhanced expression of V-ATPase subunits or with increased V-ATPase activity (43). 
Endolysosomal pH monitoring by LysoTracker® dye was performed in HMLE Twist1-ER 
cells upon EMT induction for selective visualization of acidic organelles, in which the dye 
accumulates and stains them. Comparing control and 4-OH-TX-treated HMLE Twist1-ER 
cells a slight increase of cells with acidic compartments could be seen, suggesting 
increased V-ATPase activity. Acidification of lysosomes was markedly diminished upon  
V-ATPase inhibition by Archazolid A (Figure 12).  
 
Figure 12: Archazolid A inhibits V-ATPase activity of HMLE Twist1-ER cells after EMT. LysoTracker® staining 
of acidic endolysosomal compartments (red) of HMLE Twist1-ER cells without (epithelial, epi) and with EMT 
induction by 20 nM 4-OH-TX and with/without Archazolid A (Archa A) treatment in indicated concentrations 
is shown. Nuclei (blue) were stained with 5 µg/ml Hoechst 33342. Scale bars 20 µm (n=2).  
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No difference between the protein and mRNA expression of V-ATPase subunit c between 
epithelial and mesenchymal HMLE Twist1-ER cells were seen, as shown by Western blot 
and qRT-PCR analysis (Figure 13A, B).  
 
Figure 13: V-ATPase expression is comparable in epithelial and mesenchymal HMLE Twist1-ER cells. (A) 
Protein expression of V-ATPase in epithelial (epi) and mesenchymal (mes) HMLE Twist1-ER cells with  
anti-V-ATPase (Ductin ATPV0C) and anti-actin antibodies is shown (Student´s t-test, SEM, ns=not significant, 
n=3) (B) mRNA expression of V-ATPase (Ductin ATP6V0C) in epithelial and mesenchymal HMLE cells is 
shown. (Student´s t-test, SEM, ns= not significant, n=3). 
 
3.2.2 Archazolid A treatment during EMT impedes migration and mammosphere 
formation of HMLE cells 
3.2.2.1 Archazolid A treatment during EMT inhibits migration 
Impaired motility of invasive breast cancer cells upon V-ATPase inhibition has been shown 
in recent years (43, 46, 47). However, the role of V-ATPase on migration during EMT is 
unknown to date. To investigate whether Archazolid A inhibits EMT-induced migration, 
HMLE cells were pretreated with Archazolid A for 24 h before EMT induction. The 
transwell migration assay revealed that the induced migratory ability of mesenchymal 
HMLE Twist1-ER cells was successfully inhibited with Archazolid A treatment (Figure 14). 
This result indicates an important function for V-ATPase during EMT on migration. 
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Figure 14: Archazolid A hampers migration after induction of EMT in epithelial HMLE Twist1-ER cells. 
Transwell migration of HMLE Twist1-ER cells without (epithelial, epi) and with EMT induction by 20 nM 4-
OH-TX and with/without Archazolid A (Archa A) treatment in indicated concentrations is shown. Migrated 
HMLE Twist1-ER cells were stained with crystal violet (purple) and quantified using ImageJ cell counter. The 
graph shows the number of migrated cells after 6 h, normalized to 4-OH-TX treated cells. (One-way ANOVA, 
Tukey's Multiple Comparison Test, SEM, *p<0.05, n=4). 
3.2.2.2 Archazolid A inhibits mammosphere formation  
To analyze the role of V-ATPase on bCSC formation, mammosphere assays were 
performed. Dontu et al. developed this assay in order to evaluate the mammosphere-
forming and therefore tumor-initiating potential of cells in vitro in an ultra-low 
attachment environment (59). Mesenchymal HMLE cells that had underwent EMT showed 
increased mammosphere-forming ability and mammosphere size. The induced 
mammosphere formation was diminished significantly by Archazolid A (Figure 15A). This 
effect was not mediated by increased apoptosis upon Archazolid A treatment (Figure 15B). 
Cells which were unable to form mammospheres on the ultra-low attachment poly-HEMA 
coated plates died as shown by PI staining, whereas maintained viability of cells which 
were able to proliferate and to form mammospheres was seen (Figure 15C). Taken 
together, these results indicate a pivotal role for Archazolid A on mammosphere 
formation. 
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Figure 15: Archazolid A inhibits mammosphere formation after induction of EMT in epithelial HMLE 
Twist1-ER cells. (A) Mammosphere formation of HMLE Twist1-ER cells without (epithelial, epi) and with EMT 
induction by 20 nM 4-OH-TX for 10 days and with/without Archazolid A (Archa A) treatment in indicated 
concentrations is shown. Graphs depict mammosphere count (> 50 µm; left graph) normalized to 4-OH-TX 
treated mesenchymal controls and size (right graph). (One-way ANOVA, Tukey's Multiple Comparison Test, 
SEM, *p<0.05, n=5). (B) Nicoletti assay of cells treated with Archazolid A (1 and 10 nM) for 24 h is shown. 
(One-way ANOVA, Tukey's Multiple Comparison Test, SEM, ns=not significant, n=3). (C) 50 µg/ml PI (red) 
staining of dead cells and 5 µg/ml Hoechst 33342 staining of nuclei (blue) are shown (n=2).  
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3.2.2.3 Archazolid A sustainably prevents mammosphere formation  
For the sustainability of reduced malignancy, the maintenance of diminished 
mammosphere formation is of major importance and can be analyzed by repeated 
mammosphere assay. In second round mammosphere assays, the mammosphere-forming 
ability of 4-OH-TX-treated HMLE Twist1-ER cells was preserved and also the inhibitory 
effect of Archazolid A was still given (Figure 16).  
 
 
Figure 16: Archazolid A inhibits 2
nd
 round mammosphere formation. 1
st
 round mammospheres were 
disrupted, 20 000 viable single cells/well were reseeded in poly-HEMA coated 12-well plates and incubated 
for 7 days without further stimulation. The graphs depict mammosphere count (> 50 µm) normalized to  
4-OH-TX treated cells (left graph) and size (right graph). (One-way ANOVA, Tukey's Multiple Comparison 
Test, *p<0.05, ns=not significant, n=3). 
 
Taken together, this set of data demonstrates that Archazolid A inhibits two crucial 
functional characteristics of cancer stem cells: migration and self-renewal.  
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3.2.3 Archazolid A preserves an epithelial phenotype during EMT 
So far, the presented data point to a noticeable effect of Archazolid A treatment during 
EMT on migration and mammosphere formation. In a next step, the underlying signaling 
mechanism of EMT regulation was investigated. Quantitative RT-PCR analysis revealed 
significant decrease of epithelial E-cadherin expression upon 4-OH-TX treatment, but no 
influence of Archazolid A. The mesenchymal markers vimentin, fibronectin and N-cadherin 
showed increased expression after 4-OH-TX treatment but were also not influenced by 
Archazolid A treatment (Figure 17A). Interestingly, on protein level, epithelial E-cadherin, 
β-catenin and claudin-1 were reduced in 4-OH-TX treated cells but strongly increased by 
Archazolid A (Figure 17B). In line, the increased expression of the mesenchymal markers, 
fibronectin and vimentin was strikingly reduced upon Archazolid A stimulation. These 
results were confirmed by staining of EMT markers: epithelial E-cadherin and β-catenin 
were visible at the cell membrane and clearly diminished upon 4-OH-TX treatment. Both 
epithelial markers were enhanced upon Archazolid A treatment. Mesenchymal vimentin 
and N-cadherin were visible in the 4-OH-TX-induced HMLE Twist1-ER cells and signals 
were decreased by Archazolid A stimulation (Figure 17C). These results suggest a  
post-translational regulation of EMT markers upon V-ATPase inhibition. 
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Figure 17: Effects of Archazolid A on EMT marker. (A) mRNA expression of E-cadherin, vimentin, fibronectin 
and N-cadherin without (epithelial, epi) and with EMT induction by 20 nM 4-OH-TX and with/without 
Archazolid A (Archa A) treatment in indicated concentrations is shown. (One-way ANOVA, Tukey's Multiple 
Comparison Test, SEM, *p<0.05, ns=not significant, n=3). (B) Immunoblots of HMLE Twist1-ER cells without 
and with EMT induction by 20 nM 4-OH-TX and with/without Archazolid A in indicated concentrations 
probed with anti-E-cadherin, anti-claudin, anti-β-catenin, anti-fibrnectin, anti-vimentin and anti-β-tubulin 
antibodies are shown (n=3). (C) Immunostainings with anti-E-cadherin, anti-β-catenin, anti-vimentin and 
anti-N-cadherin antibodies (green) and 5 µg/ml Hoechst 33342 (blue) are shown. Scale bars 10 µm (n=3). 
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3.2.4 TGF-β-induced EMT is inhibited by Archazolid A 
TGF-β plays an important role in EMT and possesses a crucial part in tumor progression, 
thus it was used as an alternative inducer for EMT (22). Confirming previous results, 
Archazolid A significantly inhibited the TGF-β-induced mammosphere formation  
(Figure 18A). In line, Archazolid A treatment was able to abrogate TGF-β-mediated 
decrease of E-cadherin protein expression and could also diminish enhanced vimentin 
expression (Figure 18B). Additionally, the EMT marker staining confirmed these results 
(Figure 18C). Especially for β-catenin, the TGF-β-treated HMLE Twist1-ER cells showed 
accumulation of β-catenin in cellular vesicles. Interestingly, Archazolid A-treated cells 
showed enlarged intracellular β-catenin bodies. N-cadherin signal was strongly decreased, 
particularly in the 10 nM Archazolid A-treated cells. These findings indicate that Archazolid 
A is able to successfully inhibit TGF-β-induced EMT, suggesting a general influence of  
V-ATPase on EMT. 
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Figure 18: Archazolid A inhibits TGF-β-induced EMT. (A) Mammosphere formation without (epithelial, epi) 
and with EMT induction by 5 ng/ml TGF-β for 12 days and with/without Archazolid A (Archa A) treatment in 
indicated concentrations is shown. Graph depicts mammosphere count (> 50 µm) normalized to TGF-β-
treated cells. (One-way ANOVA, Tukey's Multiple Comparison Test, SEM, *p<0.05, ns=not significant, n=3). 
(B) Immunoblots of HMLE Twist1-ER cells without and with EMT induction by TGF-β and with/without 
Archazolid A treatment in indicated concentrations probed with anti-E-cadherin, anti-vimentin antibodies 
and a prestained gel as loading control are shown (n=3). (C) Immunostaining with anti-E-cadherin,  
anti-β-catenin, anti-vimentin and anti-N-cadherin antibodies (green) and 5 µg/ml Hoechst 33342 (blue) are 
shown. Scale bars 25 µm (n=3). 
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3.2.5 Archazolid A impedes Notch1-induced signaling 
Notch1 signaling is also known to be regulated by endolysosomal pathways (61) and to 
induce EMT(62). Deregulated Notch1 signaling is implicated in CSC promotion of primary 
and metastatic tumors and known to regulate both: the acquisition of a mesenchymal 
phenotype and the formation of CSC (62, 63). In preliminary studies, we showed  
that basal Notch1 levels are enhanced upon Archazolid A treatment in MCF-7 and  
MDA-MB-231 cells (Figure 19A). EGTA-induced Notch1 signaling was abrogated  
upon Archazolid A treatment as shown by markedly diminished NICD (Figure 19B).  
In line, Notch1 staining revealed an enhanced accumulation of Notch1 in intracellular 
compartments by Archazolid A treatment (Figure 19C). Together, with the results from 
TGF-β-induced EMT, this set of data strengthens the assumption that Archazolid A in 
general regulates endolysosomal pathways, which are associated with EMT. 
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Figure 19: Notch1 signaling is diminished upon Archazolid A stimulation. (A) Immunoblots of MCF-7 and 
MDA-MB-231 without (co) and with Archazolid A (Archa A) treatment in indicated concentrations probed 
with anti-Notch1 and anti-β–tubulin antibodies control are shown (n=2). (B) Immunoblots of MCF-7 and 
MDA-MB-231 without (co) and with 24 h Archazolid A (1 or 10 nM) treatment and with/without subsequent 
500 nM EGTA stimulation for 2.5 h is shown. Samples were probed with anti-NICD and anti-β-tubulin 
antibodies (n=2). (C) Immunostaining with anti-Notch1 antibody (green) and 5 µg/ml Hoechst 33342 (blue) is 
shown. Scale bars 25 µm (n=2). 
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3.2.6 V-ATPase knockdown inhibits EMT 
In order to analyze whether the seen functional and signaling effects of Archazolid A are 
attributed to the V-ATPase, the V0 subunit c of the V-ATPase, which is the binding site for 
Archazolid A, was knocked down. HMLE Twist1-ER cells were stably transduced with an 
IPTG-inducible V-ATPase shRNA vector. Out of the five V-ATPase shRNA transductions, 
most effective knockdown of V-ATPase shRNA was achieved in clone 1 (to 30 %) and clone 
3 (to 10 %) upon IPTG treatment (Figure 20A). Downregulation of V-ATPase was confirmed 
by LysoTracker® staining, which showed decreased acidification of lysosomes upon IPTG 
treatment (Figure 20B). Notably, the mammosphere-forming potential was strongly 
inhibited in the V-ATPase shRNA knockdown clones (Figure 20C). Similar to Archazolid A 
treatment the protein expression of the EMT marker shifted to rather epithelial than 
mesenchymal properties, as confirmed by β-catenin and vimentin staining (Figure 20D). 
These findings support the assumption that V-ATPase plays a crucial role during EMT. 
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Figure 20: V-ATPase knockdown reduces mammosphere formation and promotes epithelial 
characteristics. (A) Expression of V-ATPase subunit c in non-targeting (nt) and V-ATPase shRNA HMLE 
Twist1-ER clones (1 and 3) after 1 mM IPTG treatment for 96 h is shown. (One-way ANOVA, Tukey's Multiple 
Comparison Test, SEM, *p<0.05, n=3). (B) Acidic endolysosomal compartments are shown by LysoTracker® 
staining (red) in HMLE Twist1-ER cells with/without 1 mM IPTG treatment. Nuclei were stained with 5 µg/ml 
Hoechst 33342 (blue). Scale bars 25 µm (n=3). (C) Mammosphere assay with nt shRNA cells without EMT 
induction and nt and V-ATPase shRNA cells with EMT induction by 4-OH-TX is shown. Graph depicts number 
of mammospheres counted (> 50 µm). (One-way ANOVA, Tukey's Multiple Comparison Test, SEM, *p<0.05, 
n=3). (D) Immunostaining with nt shRNA cells without EMT induction and nt and V-ATPase shRNA cells with 
EMT induction, probed with anti-β-catenin, anti-vimentin (green) antibodies and 5 µg/ml Hoechst 33342 
(blue) is shown. Scale bars 10 µm (n=3). 
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3.2.7 E-cadherin internalization is repressed by Archazolid A 
Our data convincingly demonstrated a crucial role for V-ATPase on EMT. A main event in 
this occurrence is the enhanced internalization and degradation of E-cadherin (64).  
In order to elucidate the mechanism underlying impaired EMT upon V-ATPase inhibition, 
surface E-cadherin internalization was analyzed. As this is a dynamic process,  
not only cell surface E-cadherin was detected in epithelial HMLE cells, but also a distinct 
part was internalized after 20 min, which was recycled back to the cell membrane  
(Figure 21). Expectedly, 4-OH-TX treatment diminished surface and cytosolic E-cadherin, 
indicating the already initiated transition. Archazolid A treatment strongly increased  
initial membranous E-cadherin compared to solely 4-OH-TX-treated cells. In the course of 
20 min, E-cadherin was accumulated intracellulary, while it also remained at the cell 
surface by low dose treatment. Of note, in the 10 nM Archazolid A-treated cells,  
E-cadherin surface and intracellular localization was strongly diminished. Taken together, 
disturbed internalization as well as increased intracellular accumulation of E-cadherin 
upon Archazolid A treatment promotes E-cadherin patterns which resemble epithelial 
cells. 
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Figure 21: EMT-induced internalization of E-cadherin is diminished by Archazolid A. Surface E-cadherin 
(HECD1, green) recycling of HMLE Twist1-ER cells without (epithelial, epi) and with EMT induction by 4-OH-
TX and with/without Archazolid A (Archa A) treatment in indicated concentrations is shown. Subsequent to 
surface E-cadherin staining, cells were fixed after 0, 5, 10, and 20 min of recycling at 37 °C and 5 % CO2. 
Nuclei were stained with 5 µg/ml Hoechst 33342 (blue). Images were taken using Leica-SP8 confocal 
microscope. Scale bars 10 µm (n=3). 
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3.2.8 E-cadherin recycling is inhibited upon V-ATPase inhibition 
In search for the cause of enhanced surface as well as intracellular E-cadherin upon  
V-ATPase inhibition during EMT, a more detailed analysis of the endolysosomal 
compartments was performed. The early endosomal marker Rab5 endorses the fusion of 
early endosomes, containing endocytosed molecules as E-cadherin, and thus serves to 
enhance their transport either back to the cell membrane or to lysosomes for 
degradation. In control cells, E-cadherin was localized mainly on the membrane and was 
also intracellulary distributed (Figure 22A). Rab5 also showed a diffuse distribution  
in the cell. To the contrary, in mesenchymal HMLE Twist1-ER cells, E-cadherin was strongly 
diminished at cell-cell contacts and localized mainly in the nuclei. Here, Rab5 was 
predominantly localized in perinuclear clusters congruent with E-cadherin. V-ATPase 
shRNA clones treated with 4-OH-TX exhibited enlarged Rab5-positive endosomes, which 
contained E-cadherin. 
Rab7 labels late endosomes as it promotes the carriage of endosomal E-cadherin from 
early endosomes towards the lysosome instead of its recycling back to the cell membrane 
(65). In control HMLE Twist1-ER cells E-cadherin was present at cell-cell junctions, whereas 
Rab7 was located in the perinuclear area (Figure 22B). In mesenchymal cells, E-cadherin 
was distributed within the cell and located strongly in the nucleus of the cells. Also, 
colocalization of E-cadherin and Rab7 could be seen. Interestingly, in V-ATPase shRNA 
clone 3, enlarged E-cadherin- and Rab7-positive compartments were visible. Furthermore, 
E-cadherin was clearly increased at cell-cell contacts, while it was not colocalized with 
Rab7. This result was confirmed by EMT induction with TGF-β (Figure 22C). 
Immunostaining for the lysosomal-associated membrane glycoprotein 1 (LAMP-1) and  
E-cadherin were made in order to investigate lysosomal-localized E-cadherin (Figure 22D). 
In control cells, LAMP-1 was accumulated and localized intracellulary upon 4-OH-TX 
stimulation and E-cadherin was colocalized in LAMP1-positive compartments. Remarkably, 
the amount of E-cadherin protein on the cell surface was increased upon Archazolid A 
treatment. Additionally, in the Archazolid A-treated HMLE Twist1-ER cells, E-cadherin was 
increased not only on the cell surface but is also trapped in lysosomes, especially 
perinuclearly. This set of data point to the fact that the carriage of E-cadherin from 
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endosomal to lysosomal compartments is inhibited by V-ATPase inhibition, suggesting 
impeded EMT by diminished E-cadherin degradation.  
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Figure 22: E-cadherin is trapped in early endosomes but is not processed to late lysosomes during EMT.  
(A) Immunostaining of E-cadherin (HECD1; green) and Rab5 (red) of nt shRNA cells without EMT induction 
and of nt and V-ATPase shRNA cells with EMT induction is shown. Colocalization (orange, arrowheads) was 
revealed by double immunofluorescence. Nuclei were stained with Hoechst 33342 (blue). Scale bars 25 µm 
(n=2). (B, C) Immunostaining of E-cadherin (HECD1; green) and Rab7 (red) of nt shRNA cells and of nt and  
V-ATPase shRNA cells with EMT induction by 4-OH-TX (B) or TGF-β (C) is shown. Colocalization (orange) was 
revealed by double immunofluorescence. Nuclei were stained with Hoechst 33342 (blue). Scale bars 25 µm 
(n=3). (D) Immunostaining of HMLE Twist1-ER cells without (co) and with EMT induction by 4-OH-TX and 
with/without Archazolid A (Archa A) treatment in indicated concentrations is shown for the proteins:  
E-cadherin (green), LAMP1 (red). Nuclei were stained with 5 µg/ml Hoechst 33342 (blue). Merged signals are 
depicted in orange. Scale bars 10 µm (n=3). 
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3.3 Archazolid A reduces migration and mammosphere 
formation of mesenchymal HMLE cells 
So far, our data convincingly show that EMT and bCSC formation were successfully 
inhibited by V-ATPase inhibition. Yet, it is also of clinical outmost importance to target 
already existing, poorly accessible CSC. In order to investigate if V-ATPase inhibition 
exhibits a debilitating effect on preexisting CSC, fully transitioned mesenchymal HMLE 
cells were used. These cells comprise stem cell-like characteristics, such as enhanced 
motility and mammosphere-forming ability.  
3.3.1 Archazolid A reduces migration of mesenchymal HMLE cells 
Initially, the role of V-ATPase on the migration of mesenchymal HMLE cells was examined. 
Treatment with Archazolid A (1 nM and 10 nM) significantly inhibited migration as shown 
by Boyden chamber experiments (Figure 23A). An apoptotic effect of Archazolid A on the 
cells during treatment and migration could be excluded, as shown by Nicoletti assay 
(Figure 23B). 
 
Figure 23: Archazolid A inhibits migration of mesenchymal HMLE cells. (A) Transwell migration of HMLE 
cells prestimulated with/without Archazolid A (1 or 10 nM) for 24 h determined by Boyden chamber 
experiments is shown. Graph displays the number of migrated cells after 6 h normalized to positive control 
(PC). For negative control (NC), medium without FCS was added. (One-way ANOVA, Tukey's Multiple 
Comparison Test, SEM, *p<0.05, n=3). (B) Apoptosis rate of HMLE cells after 24 h Archazolid A (1 nM and 10 
nM) treatment is shown. (One-way ANOVA, Tukey's Multiple Comparison Test, SEM, ns=not significant, 
n=3). 
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3.3.2 Archazolid A reduces mammosphere formation in mesenchymal HMLE cells 
The ability of mesenchymal HMLE cells to form mammosphere formation was significantly 
inhibited by Archazolid A treatment (Figure 24). These results indicate an important role 
of V-ATPase on cancer stem cell-like traits.  
 
Figure 24: Archazolid A inhibits mammosphere formation of mesenchymal HMLE cells. Mammosphere 
formation of mesenchymal HMLE cells with/without 1 nM Archazolid A treatment for 24 h is shown. Images 
were taken with Zeiss LSM 510 Meta confocal microscope and mammospheres > 50 µm were counted. The 
graph displays the mammosphere count related to untreated control (Student´s t-test, SEM, *p<0.05, n=3).
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4 DISCUSSION 
Inhibiting the genesis of cancer stem-like cells in order to diminish progression of cancer is a 
very new and promising approach. In recent years, a pivotal role for EMT in cancer 
metastasis has been postulated. So far, only TGF-β-induced EMT inhibition was successful in 
clinical trials (66, 67), hence further strategies are urgently needed to overcome  
EMT-induced metastasis. This work introduces V-ATPase inhibition as a promising new 
strategy to diminish bCSC formation by impeded EMT.  
4.1 EMT, CSCs and the relevance of V-ATPase in this context 
EMT programs emerged as important regulators for cancer cells, for example by mediating 
their transition into stem-like cells. Evidence indicates that the EMT program is used by both, 
normal epithelial as well as neoplastic carcinoma cell populations, to gain stem cell-like traits 
(2, 68). In fact, pleiotropically acting transcription factors, such as Twist1, are known to 
induce EMT when expressed in epithelial cells and have also been linked to self-renewal 
programs in cancer cells. Indeed, Twist1 overexpression in epithelial HMLE Twist1-ER cells is 
associated with poor clinical outcome in cancers such as bladder cancer, oral squamous cell 
carcinoma, ovarian cancer, cervical cancer as well as breast cancer (69-73). Hence, the 
investigation of the Twist1-mediated EMT induction in this work is highly important in order 
to develop new treatment options.  
Much is still to be learned about the machinery of EMT regulation. In fact, elevated V-ATPase 
expression and activity are well described for cells which have undergone EMT and are highly 
invasive (74, 75). Although, enhanced V-ATPase expression in fully transitioned mesenchymal 
HMLE cells could not be confirmed in this work, our results indicate increased V-ATPase 
activity upon EMT induction. Of note, the abrogated V-ATPase activity by Archazolid A 
treatment was clearly visible. To this end, our study intended to establish a new strategy to 
address the clinical relevant issue of targeting EMT and therefore CSCs by the inhibition of 
the V-ATPase. 
Although, an increasing number of CSC-targeting therapies emerged in recent years, only 
very few showed promising results in clinic. In detail, several Notch pathway inhibitors were 
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clinically tested, but revealed cytotoxic effects. Yet, novel γ-secretase inhibitors in 
combination with chemotherapy reduced bCSCs in patients (76). Indeed, in our study we 
could show that Archazolid A inhibition in malignant breast cancer cells also affected the 
Notch1 activation, suggesting this drug to be a further potent inhibitor of CSCs. Moreover, 
the monoclonal antibody catumaxomab, which consists of anti-EpCAM and anti-CD3, showed 
improved quality of life in clinical phase II and III studies (77). A further clinically important 
inducer of EMT and metastasis is the cytokine TGF-β. Indeed, compounds which are able to 
bloc TGF-β-induced EMT, such as galunisertib and fresolimumab revealed successful anti-
tumor activity in clinical trials (66, 67). This prompted us to investigate the role of V-ATPase 
in TGF-β-mediated signaling, which indeed revealed promising anti-tumor effects in vitro. 
The encouraging, yet very few clinical reports pave the way for further therapeutic 
investigations on CSC therapy. In this work we show that V-ATPase inhibition interferes with 
diverse EMT-mediating pathways, such as Twist1, TGF-β and Notch 1. Hereby, we introduce 
the V-ATPase as a new druggable target for EMT inhibition and thus CSC formation and by 
this perform pioneer work.  
4.2 V-ATPase inhibition diminishes cancer stem cell-like traits and 
promotes epithelial characteristics 
During recent years, V-ATPase has proven to be a very promising target for cancer therapy. 
Yet, major part of the previous work focused on the implication of V-ATPase in cancer cell 
metastasis, invasion, tumor cell death and anoikis resistance (35, 43, 46, 47, 56). In fact, 
metastasis is the main cause for cancer-induced mortality (78). Of note, EMT is increasingly 
accepted to preserve a crucial role in tumor metastasis. Thus, pharmacological targeting may 
represent an effective strategy to inhibit metastasis. Up to now, only very few reports 
investigate the crosstalk between V-ATPase and EMT in cancer cells (3).  
Mani et al. revealed that EMT induction by Twist1 or Snail1 transcription factors in human, 
non-tumorigenic mammary epithelial cells promotes a mesenchymal phenotype and exhibits 
bCSC like characteristics (2). This knowledge enables fundamental investigations during the 
course of EMT. Utilizing this model, research on the significance of V-ATPase during the 
course of EMT was successfully performed in this work.  
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We for the first time showed that targeting V-ATPase through specific gene knockdown or 
pharmacological inhibition abrogates sustainably EMT-induced bCSC formation, migration 
and expression of stem cell markers. In detail, this work disclosed that enhanced 
mammosphere formation upon EMT was abolished by Archazolid A and stable V-ATPase 
subunit c shRNA knockdown. Most notably, the demonstrated sustainability of this effect 
may improve long term survival in breast cancer patients. These findings indicate that  
V-ATPase is involved in the acquisition and most notably in the maintenance of bCSC. 
Moreover, we could show that EMT-induced downregulation of the epithelial E-cadherin,  
β-catenin and claudin-1 proteins was successfully abrogated by Archazolid A. Notably, 
mesenchymal vimentin, fibronectin and N-cadherin overexpression in cancer is correlated 
with metastasis and thus poor prognosis (79-84). Indeed, we could show that enhanced 
protein expression of these markers was strongly reduced upon V-ATPase inhibition, whereas 
transcriptional regulation was not influenced by V-ATPase during EMT. Therefore, V-ATPase 
is suggested to regulate EMT on a post-transcriptional level.  
Consistent with these findings, TGF-β-mediated EMT-induction and therefore the 
accompanied gain of mesenchymal traits, were successfully diminished by V-ATPase 
inhibition. The effective decrease of mammosphere-forming ability by Archazolid A 
treatment suggests a promising new strategy to target metastasis. Taken together, rising 
evidence points to the fact that V-ATPase inhibition overall preserves epithelial 
characteristics in HMLE cells.  
4.3 E-cadherin: the major player in V-ATPase-related EMT  
A hallmark in the advent of EMT is the post-translational loss of E-cadherin, which can be 
used as a direct predictor of negative clinical outcome (85). Indeed, several studies showed 
evidence that it is of major importance for metastasis in vitro and in vivo (86-88). Onder et al. 
revealed that E-cadherin loss, and with that cell-cell dissemination, is pivotal for EMT 
induction in mammary epithelial breast cells (89). Notably, E-cadherin trafficking is balanced 
by endolysosomal pathways, which in turn are dependent on the ability of V-ATPase to 
acidify the respective compartments (4, 28). According to recent reports, a general influence 
of V-ATPase inhibition on internalization, degradation as well as recycling processes back to 
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the cell membrane is evident. For example, V-ATPase inhibition by Archazolid was shown to 
alter EGFR localization and to reduce its internalization after long time treatment (47). 
Moreover, it has also shown to inhibit transferrin/transferrin-R uptake in breast cancer cells 
(35). In order to investigate the role of V-ATPase on E-cadherin signaling during EMT, we 
utilized an in vitro EMT-mimicking model by using Twist1-inducible HMLE cells. Substantial  
E-cadherin repression upon EMT induction occurred not until 8 days after initial Twist1 
translocation into the nucleus. This delayed response, can be explained by the fact that 
Twist1 binds to the E-box on the Snail2 promoter to activate its transcription. Only after 
Snail2 expression, E-cadherin expression is suppressed (32). Interestingly, Twist1-mediated 
EMT induction reduced cell surface E-cadherin compared to epithelial control, whereas 
treatment with Archazolid A during EMT increased surface E-cadherin as well as enhanced 
intracellular E-cadherin.  
Rab5 is known to be the major regulator of endocytosis by controlling the biogenesis and 
fate of early endosomes. From here, E-cadherin is either recycled back to the plasma 
membrane or degraded by the lysosomal pathway, which in turn is mediated by Rab7 (90). In 
fact, our presented results indicate a pivotal role for V-ATPase-mediated endolysosomal 
shuttling of E-cadherin. In detail, upon V-ATPase inhibition, E-cadherin remained in  
Rab5-positive early endosomes and was not translocated to lysosomal compartments via the 
Rab5-Rab7-LAMP1 axis. Hence, intracellular accumulation of E-cadherin presumably  
impeded further internalization from cell surface. It remains to be elucidated, if endosomal  
E-cadherin is shuttled back to the cell membrane, possibly by a delayed recycling or 
permanently remains in the endosomes (Figure 25). Therefore, the velocity and directions of 
E-cadherin trafficking may be investigated by live cell E-cadherin imaging. In line with Onder 
et al., we confirm that deprivation of E-cadherin is necessary to induce EMT and a sole 
disruption of surface E-cadherin while protein levels remain high, is not sufficient (89).  
Remarkably, we revealed in this work the underlying mechanism of how V-ATPase regulates 
E-cadherin dynamics. We were able to show, that pharmacological V-ATPase inhibition 
results in preserved E-cadherin protein and therefore supports the epithelial-like phenotype. 
By this, the diminished functional effects on mammosphere formation and migration can be 
explained.  
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Figure 25: Proposed influence of V-ATPase inhibition on E-cadherin recycling. After E-cadherin internalization, 
endocytic vesicles fuse with the early endosome (EE), where proteins destined for degradation are sorted and 
transported either to the lysosome or are recycled back to the cell membrane. Our results suggest that  
V-ATPase inhibition prevents the internalization of E-cadherin. Furthermore, we postulate that in the rapid 
dynamic process of E-cadherin recycling, already internalized surface protein at the time of V-ATPase inhibition 
is trapped in Rab5-positive EE and is not delivered to lysosomes. From here, E-cadherin may move back to the 
cell surface by either taking a fast recycling route directly from the EE or a slower route via the ERC. However, 
this needs to be elucidated in future studies. EE, early endosome; ERC, endocytic recycling compartment; 
LAMP1, lysosomal associated membrane protein 1; EMT, epithelial-mesenchymal transition; TF, transcription 
factor. 
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4.4 Archazolid A inhibits preexisting mesenchymal traits  
Besides inhibiting EMT and therefore CSC formation, targeting of already existing CSCs 
represents an important goal regarding the improvement of cancer therapy. So far, the 
genesis of EMT-induced CSCs has been discussed. However, recent reports point to the fact, 
that V-ATPase inhibition is also a promising approach to target preexisting CSCs (74, 75). 
Indeed, inhibiting V-ATPase in embryonic rhabdomyosarcoma disease has shown to eradicate 
CSCs (75). Furthermore, pharmacological V-ATPase inhibition by bafilomycin A1, a first 
generation V-ATPase inhibitor, and its genetic knockdown diminished glioblastoma 
neurosphere forming ability and suppressed expression of stem cell markers (74).  
In this work, we introduce the inhibition of V-ATPase not only as a novel strategy to abrogate 
EMT-mediated CSC formation, but also as a pharmacologically accessible target to diminish 
preexisting malignant CSCs. In detail, we successfully showed that Archazolid A impedes 
migration and mammosphere formation in mesenchymal CSC-like HMLE cells, suggesting a 
requirement for proton pump activity in mesenchymal breast epithelia cells. 
4.5 Targeting of EMT in clinic: advantages and limitations  
In recent years, a growing body of evidence revealed a clinical relevance for EMT-induced 
cancer cell intravasation and metastatic dissemination in the progression of breast cancer 
(91-93). Thus, the inhibition of EMT induction is suggested as a potent new treatment 
strategy for patients with high risk of developing metastasis. Yet, these approaches have 
advantages but also possible limitations in the context of developing effective clinical agents.  
In detail, targeting EMT induction is severely limited for patients with preexisting metastasis 
at the time of diagnosis. Yet, agents like Archazolid A might still be of benefit, as they also 
affect malignant traits of preexisting stem-like cells. Hence, Archazolid A may be highly 
effective as adjuvant therapy to prevent early metastasis. 
Furthermore, the success of the therapy might also be limited as other EMT-inducing 
pathways arise upon suppression of another. This work focused mainly on the repercussions 
of Twist1 and TGF-β signaling inhibition. One potential alternative EMT-inducing pathway 
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may be Notch1 signaling. In fact, first hints indicate that Notch1 signaling induction can be 
diminished upon pharmacological inhibition of the V-ATPase.  
A further implication of impeding EMT is associated with resistance to chemotherapy and 
radiation. For example, non-small cell lung carcinoma cells appear to be less sensitive to 
cisplatin and paclitaxel treatment upon EMT induction with either EGF or TGF-β (94, 95). The 
approach of EMT inhibition as early adjuvant therapy may increase the sensitivity of cancer 
cells to chemotherapeutics, thereby shortening the duration of therapy and reducing the 
possibility of relapse.  
By discussing the benefits for EMT targeting, it has to be taken into account that by this, 
epithelial traits are promoted and mesenchymal characteristics are impeded, thereby 
encouraging MET. MET is a process, which enables circulating tumor cells to exit the 
bloodstream and to form metastatic tumors (96). At the same time, targeting MET may 
promote the mesenchymal phenotype and thus drive therapy resistance in premetastatic 
cancers. These issues necessitate a personalized cancer treatment, depending on the cancer 
type and stage of cancer progression.  
Furthermore, targeting existing or the development of cancer stem cells is a highly sensitive 
approach. Obtaining specificity is urgently required in order to spare normal stem cells. One 
successful attempt to acquire specificity in therapy was the linkage between a specific 
monoclonal antibody which recognizes known bCSC markers and an anti-metastatic prodrug 
(97, 98). 
Conclusively, EMT appears to have a pivotal role in cancer metastasis. Nevertheless, in future 
it will be of outmost importance to have a better understanding of cancers in which EMT is 
essential. The identification of appropriate cancer stage-dependent biomarkers may be a key 
step towards the clinical use of pharmacological agents, leading to personalized cancer 
treatment.  
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4.6 Conclusion and further perspectives 
This study for the first time presents a novel and pivotal function of V-ATPase in EMT-induced 
motility and bCSC formation. V-ATPase was shown to be a major determinant of E-cadherin 
recycling processes. Pharmacological and genetic targeting of V-ATPase during EMT 
remarkably abrogated malignant stem-like traits. Furthermore, Archazolid A successfully 
inhibited migration and mammosphere formation in cancer stem-like cells. 
This study shows highly promising results in targeting EMT-associated stemness by V-ATPase 
inhibition. Therefore it enables promising new options for further research on the in vivo 
efficacy. Additionally, combinatorial treatment of clinically approved chemotherapeutics with 
Archazolid A as adjuvant therapy in regards of diminished resistance remains a highly 
worthwhile approach for future studies.  
 
Concluding, this work provides first evidence for targeting EMT by V-ATPase inhibition as a 
promising approach to inhibit malignant cancer stem-like traits in mammary breast epithelial 
cells in vitro. Hence, this may evolve as highly beneficial in therapeutic targeting of breast 
cancer in patients with a high potential to develop lethal metastasis.  
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6 APPENDIX 
6.1 Abbreviations 
4-OH-TX   4-hydroxytamoxifen 
ANOVA   Analysis Of Variance 
APS    Ammoniumpersulfat 
bCSC    Breast cancer stem cell 
bFGF    Basic Fibroblast Growth Factor 
BPE    Bovine Pituitary Extract 
BSA    Bovine Serum Albumin 
DMSO    Dimethylsulfoxide 
DNA    Deoxyribonucleic acid 
DTT    Dithiothreitol 
ECL    Enhanced Chemiluminescence 
ECM    Extracellular matrix 
EDTA    Ethylenediaminetetraacetic acid 
EGF    Epidermal Growth Factor 
EGTA    Ethylene glycol tetraacetic acid 
EMT    Epithelial mesenchymal transition 
FCS    Fetal calf serum 
h    hour(s) 
HCl    Hydrogen chloride  
HFS    Hypotonic fluorochrome solution 
HGF    Hepatocyte growth factor 
HMLE    Human Mammary Large T Epithelial cell 
HRP    Horseradish peroxidase 
IPTG    Isopropyl β-D-1-thiogalactopyranoside 
KH2PO4   Monopotassium phosphate 
LAMP-1   Lysosomal Associated Membrane Protein-1 
ME(C)GM   Mammary Epithelial (Cell) Growth Medium   
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MET    Mesenchymal epithelial transition 
MgCl2    Magnesium chloride 
min    minutes 
MOI    Multiplicity of Infection 
Na2HPO4   Disodium phosphate  
Na3VO4   Sodium orthovanadate 
NaCl    Sodium chloride 
NaF    Sodium fluoride 
N-cadherin   Neural-cadherin 
PBS    Phosphate buffered saline 
PFA    Paraformaldehyde 
PI    Propidium iodide 
PMSF    Phenylmethanesulfonyl fluoride 
Poly-HEMA   Poly-(hydroxyethyl)-methacrylate 
RIPA    Radioimmunoprecipitation assay buffer 
RT    Room temperature 
SDS-PAGE   Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
SEM    Standard Error of the Mean 
shRNA    small hairpin ribonucleic acid 
T-BST    Tris-Buffered Saline and Tween 20 
TCE    2, 2, 2-Trichlorethanol 
TEMED   Tetramethylethylenediamine  
TGF-β    Transforming growth factor-β 
TNS    Trypsin Neutralizing Solution 
TRIS    Tris-(hydroxymethyl)-aminomethane  
Twist1-ER   Twist1-estrogen receptor 
V-ATPase   Vacuolar-type H
+
-ATPase 
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ABSTRACT
Therapeutic success of VEGF-based anti-angiogenic tumor therapy is limited 
due to resistance. Thus, new strategies for anti-angiogenic cancer therapy based on 
novel targets are urgently required. Our previous in vitro work suggested that small 
molecule Cdk5 inhibitors affect angiogenic processes such as endothelial migration 
and proliferation. Moreover, we recently uncovered a substantial role of Cdk5 in the 
development of lymphatic vessels. Here we pin down the in vivo impact of endothelial 
Cdk5 inhibition in angiogenesis and elucidate the underlying mechanism in order 
to judge the potential of Cdk5 as a novel anti-angiogenic and anti-cancer target.  
By the use of endothelial-speciic Cdk5 knockout mouse models and various endothelial 
and tumor cell based assays including human tumor xenograft models, we show 
that endothelial-speciic knockdown of Cdk5 results in excessive but non-productive 
angiogenesis during development but also in tumors, which subsequently leads to 
inhibition of tumor growth. As Cdk5 inhibition disrupted Notch function by reducing 
the generation of the active Notch intracellular domain (NICD) and Cdk5 modulates 
Notch-dependent endothelial cell proliferation and sprouting, we propose that the 
Dll4/Notch driven angiogenic signaling hub is an important and promising mechanistic 
target of Cdk5. In fact, Cdk5 inhibition can sensitize tumors to conventional  
anti-angiogenic treatment as shown in tumor xenograft models. In summary our 
data set the stage for Cdk5 as a drugable target to inhibit Notch-driven angiogenesis 
condensing the view that Cdk5 is a promising target for cancer therapy.
INTRODUCTION
Inhibition of angiogenesis has shown clinical 
eficacy and represents a valid approach in cancer 
therapy. Patients beneit from the combination of 
chemotherapeutics or radiation with angiogenesis 
inhibitors. The VEGF pathway is currently the 
predominant target for anti-angiogenic therapy and 
anti-VEGF biologics (Bevacizumab) or small molecule 
inhibitors (Sorafenib, Sunitinib) are given clinically 
[1]. Unfortunately, non-responsiveness or resistance to 
anti-angiogenic treatment and subsequent tumor 
recurrence and metastasis limit therapeutic success 
[β]. Thus, inding new strategies for anti-angiogenic 
therapy represents an important and challenging 
objective in cancer research.
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In this context, the Dll4/Notch pathway has 
emerged as an interesting target. In physiological 
angiogenesis, Dll4/Notch signaling regulates VEGF-
induced vessel sprouting and branching and deines tip 
and stalk cell speciication [γ]. In tumors, activation 
of the Notch pathway promotes tumor growth [4] and 
mediates resistance to chemotherapy [5]. Of note, the 
disruption of Dll4/Notch signaling results in inhibition 
of tumor growth [4–8] and was associated with excessive 
but non-productive angiogenesis and impaired tumor 
vessel perfusion [6, 7]. Consequently, the blockade of 
the Dll4/Notch pathway is considered as a promising 
option for anti-angiogenic treatment. In fact, Ȗ-secretase 
inhibitors or anti-Dll4/anti-Notch biologics are currently 
being evaluated in open clinical trials for cancer therapy 
[9, 10]. Furthermore, preclinical models indicated that 
the combination of targeting the Dll4/Notch pathway and 
anti-VEGF treatment leads to synergistic tumor growth 
inhibitory effects [5, 8]. However, little is known about 
the regulation of Dll4/Notch in tumor angiogenesis 
[9]. Moreover, the chemosensitization by combination 
therapies to overcome resistance to anti-angiogenic 
treatment demands more attention in order to develop new 
treatment strategies.
In this respect the protein kinase cyclin dependent 
kinase 5 (Cdk5) represents a particular interesting potential 
target to explore. Cdk5 is a serine/threonine kinase that 
is highly expressed in the central nervous system (CNS) 
and is essential for neuronal development and function 
[11–1γ], but its role in the periphery and in cancer is not 
well explored. During the recent years, the awareness 
about roles of Cdk5 besides the CNS has grown. Cdk5 
is expressed in various non-neuronal tissues [14–16] and 
has been implicated in various types of cancer including 
pancreatic [17–19], prostate [β0, β1], thyroid [ββ, βγ], 
glioma [β4], pituitary [β5], breast [β6], lung [β7], ovarian 
[β8], and hepatocellular [β9] cancers affecting various 
targets such as retinoblastoma protein and downstream 
cell cycle regulators [ββ, βγ], the PIKE-A-Akt pathway 
[β4], Ras-Ral signaling [17], or DNA damage response 
[β9]. Further, by applying cell-based assays, our former 
studies demonstrated that small molecule Cdk5 inhibitors 
exert anti-angiogenic properties [γ0, γ1] and that Cdk5 
regulates endothelial cell migration [γβ] which was 
restricted to in vitro assays. However, to nail down the 
in vivo signiicance of Cdk5 in the endothelium, we have 
recently generated constitutive and inducible endothelial-
speciic Cdk5 knockout mouse models, elucidating an 
indispensable requirement of Cdk5 for lymphatic vessel 
development and function [γγ].
Here, by using the endothelial-speciic Cdk5 
knockout mouse models, endothelial and tumor cells, and 
human tumor xenografts, we investigate the heretofore 
unknown in vivo function of Cdk5 in the blood vessel 
endothelium. Moreover, the contribution of endothelial 
Cdk5 to tumor angiogenesis and the underlying mechanism 
such as the Dll4/Notch driven angiogenic signaling are 
important subjects of this work.
RESULTS
Inhibition of Cdk5 in the endothelium induces 
hypervascularization
As also shown in our former study [γγ], Cdk5 is 
ubiquitously expressed in the endothelium (Figure 1A). 
Speciic disruption of Cdk5 in the mouse endothelium 
using the Cre/loxP system [γγ] changed blood vessel 
patterning during development, whereas, as we could 
show previously, blood vessel morphology was not 
affected [γγ]. In detail, constitutive knockdown of 
endothelial Cdk5 with the TieβCre promoter [γγ] 
induced hypervascularization of yolk sacs and 
skin of Cdk5l/lTieβCre embryos (Figure 1B, 1C). 
Consistent with these effects, postnatal knockdown 
of endothelial Cdk5 with a tamoxifen-inducible 
VE-Cadherin Cre promoter (Cdh5(PAC)-CreERTβ, i.e. 
VECCre [γγ, γ4]) (Supplementary Figure 1A) resulted in 
hypervascularization of the developing retina (Figure 1D). 
Moreover, hypervascularization of retinae of pups treated 
with the small molecule Cdk5 inhibitor roscovitine 
demonstrated pharmacological accessibility of Cdk5 
(Figure 1E). In sum, phenotyping of endothelial speciic 
knockout mouse models revealed an important role of 
Cdk5 in blood vessel development.
Endothelial knockdown of Cdk5 reduces 
tumor growth by promoting non-productive 
angiogenesis
To examine the inluence of endothelial Cdk5 on 
tumor growth, a syngeneic tumor model was applied. 
Tumor growth of subcutaneously implanted B16F1 
melanoma cells was reduced in Cdk5l/lVECCre mice 
(Figure βA and Supplementary Figure 1B). Analysis of 
tumor angiogenesis revealed that the number of vessels was 
increased in tumors of Cdk5l/lVECCre mice (Figure βB). 
Interestingly, tumor vessels from Cdk5l/lVECCre mice 
were smaller in comparison to tumor vessels from control 
littermates (Figure βB). Moreover, reduced smooth muscle 
cell (SMC) coverage of vessels from Cdk5 knockdown 
tumors demonstrated an increased incidence of immature 
vessels (Figure βC). Finally, the functionality of tumor 
vessels was assessed by visualizing the ability of tumor 
vessels to perfuse FITC-lectin. Whereas control mice 
tumors displayed predominant overlap of FITC-lectin and 
CDγ1 staining, tumor vessels from Cdk5l/lVECCre mice 
were much less perfused (Figure βD). This set of data 
indicates that the deletion of endothelial Cdk5 promotes 
non-productive angiogenesis, which resulted in reduced 
tumor growth.
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Figure 1: Knockdown and pharmacological inhibition of Cdk5 in the endothelium induces hypervascularization. (A) 
Expression of Cdk5 in the mouse endothelium is shown by immunostainings of the developing retina (d6) for Cdk5 (green) and collagen 
IV (red). Arteries (A) and veins (V) (left panel) are indicated. n = γ. Scale bar (left panel) 100 µm. Scale bar (right panel) 50 µm. (B) CDγ1 
stainings (green) of yolk sacs of E16.5 embryos with control and Cdk5l/lTieβCre genotype are shown. Scale bar 100 µm. Quantiication 
of branching points is displayed. t-test, SEM, *p = 0.0βγ, control: n = 1γ; Cdk5l/lTieβCre: n = 5. (C) CDγ1 stainings (green) of skin of 
E16.5 embryos with control and Cdk5l/lTieβCre genotype are shown. Scale bar 100 µm. Quantiication of branching points is displayed. 
t-test, SEM, *p = 0.004, control: n = 9; Cdk5l/lTieβCre: n = 5. (D) Isolectin B4 staining (IB4, green) and BrdU labeling (red) of retinae 
from control (n = 8) and Cdk5l/lVECCre (n = 10) pups (d6) is shown. Scale bars (upper panels) 100 µm. Scale bars (lower panels) 50 µm. 
Quantiications of the area covered by ECs (t-test, SEM, *p = 0.015), the numbers of branch points per ield (t-test, SEM, *p = 0.0γ4), of 
BrdU positive cells per ield (t-test, SEM, *p ≤ 0.001), and of sprouts per 1,000 µm vessel length (t-test, SEM, *p ≤ 0.001) is shown. (E) 
Isolectin B4 staining (IB4, green) and BrdU labeling (red) of retinae from pups (d6) treated with solvent (co, n = 8) or roscovitine (rosco, 
n = 7) is shown. Scale bars (upper panels) 100 µm. Scale bars (lower panels) 50 µm. Quantiications of the area covered by ECs (t-test, 
*p ≤ 0.001), the numbers of branch points per ield (t-test, SEM, *p = 0.005), of BrdU positive cells per ield (t-test, SEM, *p = 0.049), and 
of sprouts per 1,000 µm vessel length (t-test, SEM, *p ≤ 0.0β) is shown.
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Figure 2: Endothelial Cdk5 knockdown reduces tumor growth with hypervascularization of tumors with non-functional 
vessels. (A) Tumor growth is reduced in EC-speciic Cdk5 knockout mice. B16F1 tumors from control (co, n = 1β) and Cdk5l/lVECCre 
(n = 11) mice are shown. Time course of tumor growth (Rank Sum test, SEM, *p = 0.0β9) and quantiication of tumor weight (Rank 
Sum test, SEM, *p = 0.0γ6) is displayed. (B) Tumors from EC-speciic Cdk5 knockout mice show hypervascularization with small blood 
vessels. Staining of tumors from control littermates (co, n = 1β) and Cdk5l/lVECCre mice (n = 11) for endomucin (green) is shown. 
Scale bar 50 µm. Quantiication of vessel number (Rank sum test, SEM, *p = 0.01) and vessel size (Rank sum test, SEM, *p = 0.01) is 
shown. (C) Immature tumor blood vessels in EC-speciic Cdk5 knockout mice. Staining of tumors from control littermates (co, n = 1β) 
and Cdk5l/lVECCre mice (n = 11) for endomucin (green) and α-SMA (red) is shown. Scale bar 50 µm. Quantiication of the number 
of tumor vessels covered with SMCs (t-test, SEM, *p ≤ 0.00β) is shown. (D) Tumor vessel perfusion is impaired in EC-speciic Cdk5 
knockout mice. FITC-lectin (green) labels perfused vessels, CDγ1 (red) marks blood vessels. Colocalization of FITC-Lectin green and 
CDγ1 indicates perfused vessels. Control mice (co, n = 5) and Cdk5l/lVECCre mice (n = 4). Scale bar 100 µm. Quantiication of perfused 
tumor vessels is displayed (t-test, SEM, *p ≤ 0.001).
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Cdk5 regulates the Notch pathway in the 
endothelium
Although various targets of Cdk5 have been 
described in cancer and endothelial cells, as one mechanism 
by which Cdk5 might regulate tumor angiogenesis, 
the Notch pathway particularly attracted our attention 
since the phenotype of endothelial Cdk5 knockout mice 
resembles that of mice with defective Dll4/Notch signaling 
[γ]. In fact, genetic or pharmacologic inhibition of Cdk5 
in endothelial cells (HUVECs) impaired Dll4-induced 
Notch downstream target expression (Figure γA, γB) 
as well as Notch reporter activity (Figure γC). Consistent 
with these effects, blood vessel endothelial cells (BECs) 
from Cdk5l/lTieβCre embryos displayed reduced 
expression of Notch target genes after Notch activation 
by Dll4 (Figure γD). Furthermore, the expression of the 
Notch downstream target genes Hey1 and Heyβ was 
decreased in tumors from endothelial Cdk5 knockout 
mice (Figure γE). All these indings point to a Cdk5-Notch 
pathway for the regulation of angiogenesis. However, 
genetic or pharmacological inhibition of Cdk5 did not 
abrogate the Jagged1-induced Notch target expression 
(Figure 4A, 4B), suggesting a speciic regulation of 
Dll4-driven Notch signaling by Cdk5. 
Cdk5 regulates NICD generation
To understand the link between Cdk5 and the 
Dll4-Notch pathway, further experiments focused on the 
regulation of the Notch intracellular domain (NICD), 
the key mediator of Notch signaling [γ5]. After ligand-
induced proteolytic cleavage of the Notch receptor, 
NICD is released and translocates to the nucleus to drive 
target gene transcription before the signal is terminated 
by proteasomal degradation of NICD [γ5]. Inhibition of 
Cdk5 by either knockdown or pharmacologic approaches 
decreased Dll4-induced NICD generation (Figure 5A, 5B). 
This was not based on changed Notch receptor expression 
as Cdk5 silencing neither inluenced Notch receptor 
mRNA (Figure 5C) nor protein (Figure 5D). Furthermore, 
the inhibition of the proteasomal degradation by MG1γβ 
did not abrogate the Cdk5 siRNA mediated decrease 
of NICD (Figure 5E). To prove the functionality of 
MG1γβ, ȕ-catenin was used as a positive control as it is 
degraded by the proteasome [γ6]. Increased ȕ-catenin in 
the presence of MG1γβ proved that MG1γβ inhibited the 
proteasomal degradation (Figure 5F). In line, exogenously 
expressed NICD that is not dependent on Notch receptor 
cleavage, was not affected by Cdk5 inhibition (Figure 5G). 
Both results suggest that Cdk5 preferentially contributes 
to NICD generation rather than its degradation. Cdk5 
knockdown by siRNA as well as Cdk5 inhibition by 
roscovitine decreased levels of phosphorylated and 
total presenilin, the catalytic subunit of the Ȗ-secretase 
multiprotein complex capable of mediating NICD 
generation. (Figure 5H, 5I). This set of data suggests 
that Cdk5 provides negative tonus on Notch-dependent 
signaling.
Cdk5 regulates Notch dependent endothelial 
functions
We next asked if Cdk5 could contribute to Notch 
dependent endothelial functions like proliferation and 
sprouting of endothelial cells [γ7, γ8]. In fact, inhibition 
of endothelial Cdk5 abrogated the Dll4-mediated decrease 
of endothelial cell proliferation (Figure 6A). In line, Cdk5 
inhibition increased sprouting of spheroids embedded 
into Dll4-containing gels (Figure 6B). Moreover, in line 
with the immunoblots in Figure 5 that showed reduced 
NICD levels by Cdk5 inhibition, immunostainings suggest 
reduced NICD levels in spheroids generated from Cdk5 
siRNA treated cells (Figure 6C). Thus, inhibition of Cdk5 
impaired endothelial cell functions which are dependent 
on Dll4-driven Notch activation.
Cdk5 inhibition reduces tumor growth and 
improves sensitivity to anti-angiogenic treatment
As described above, knockout of endothelial Cdk5 
reduced tumor growth of wildtype B16F1 melanoma 
cells (Figure βA), demonstrating that endothelial Cdk5 
regulates tumor growth. To investigate the inluence of 
Cdk5 inhibition on tumor growth in a more therapeutic 
context, we used systemic treatment with the small 
molecule Cdk5 inhibitor roscovitine. Although, like 
most kinase inhibitors, roscovitine is not selective for 
the inhibition of Cdk5 but also addresses other Cdks 
like Cdk1, Cdkβ, Cdk7, and Cdk9, it represents the best-
established inhibitor for Cdk5 and therefore was used 
as a model substance for our studies [γ9–41]. We used 
a subcutaneous human U87 glioblastoma cell xenograft 
model as glioblastoma represent highly vascularized 
and aggressive tumors [4β]. Roscovitine was given after 
tumors had established and reduced glioblastoma growth 
as shown by a signiicantly reduced growth rate of tumors 
from roscovitine treated mice (Figure 7A). In endothelial-
speciic Cdk5 knockout mice, systemic treatment with 
roscovitine slightly but not signiicantly reduced tumor 
growth and decreased tumor cell proliferation as shown 
by Ki67 staining (Figure 7B). Moreover, roscovitine had 
no effect on vessel number in tumors grown in endothelial 
Cdk5 knockout mice (Figure 7B). This set of data suggests 
that Cdk5 indeed is the primary target of roscovitine, 
but that roscovitine also acts on tumor cells as well and 
inhibits other Cdks besides Cdk5. Pharmacokinetic studies 
showed plasma concentrations of roscovitine comparable 
to doses used in our cell-based assays (Figure 7C). 
Together with the reduced growth of wildtype 
tumors in endothelial Cdk5 knockout mice (Figure βA), 
this set of data provides evidence for Cdk5 as a drugable 
target for anti-angiogenic therapy. Finally, we assessed the 
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Figure 3: Cdk5 regulates the Notch pathway in the endothelium. (A) Effect of Cdk5 siRNA on Dll4-induced expression 
of Notch downstream target genes Hey1, Heyβ and NRARP, Hes1, and VEGFRβ in HUVECs is shown (One-Way ANOVA, Holm-
Sidak, SEM, *p ≤ 0.05). Cdk5 downregulation is shown (t-test, SEM, *p ≤ 0.001). n = γ. nt: non-targeting siRNA. (B) Effect of Cdk5 
inhibition by roscovitine on Dll4-induced expression of Notch downstream target genes Hey1, Heyβ and NRARP is shown (One-Way 
ANOVA, Tukey, SEM, *p ≤ 0.05). n = 6. (C) Effect of Cdk5 inhibition by roscovitine on Notch reporter gene activation is shown (ANOVA 
on Ranks, Student-Newman-Keuls, SEM, *p ≤ 0.05). n = γ. (D) Expression of the Notch downstream target genes Hey1 and Heyβ in 
blood vessel endothelial cells (BECs) from E16.5 control and Cdk5l/lTieβCre embryos is shown (t-test, SEM, *p ≤ 0.001). Expression 
of Notch target genes was induced by plating of BECs onto Dll4. Cdk5 downregulation is shown (t-test, SEM, *p ≤ 0.001). n = γ. 
(E) Expression of the Notch downstream target genes Hey1 (t-test, SEM, *p = 0.00γ) and Heyβ (t-test, *p = 0.01β) in tumors from control 
versus Cdk5l/lVECCre mice is shown. Expression of VE-Cadherin (VEC) is shown. Hey1 and Heyβ mRNA levels were normalized to VEC 
to compensate for the hypervascularization. n = 4.
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effect of anti-VEGF treatment on Lewis lung carcinoma 
(LLC) growth in endothelial-speciic Cdk5 knockout 
mice. The LLC model has been described to be resistant 
to conventional anti-angiogenic therapy [4γ]. As expected, 
the anti-VEGF antibody Bβ0–4.1.1 did not reduce LLC 
tumor growth in control mice. However, in endothelial 
Cdk5 knockout mice anti-VEGF treatment diminished 
tumor growth (Figure 8). Thus, Cdk5 inhibition enhanced 
sensitivity of tumors to anti-VEGF treatment. 
DISCUSSION
Substantial advances in understanding of 
angiogenesis have been made with regard to the regulation 
and targeting of growth factor receptors such as the 
VEGF-Receptor [1, 44, 45]. However, the inhibition 
of growth factors is not effective in all cancers [46]. 
Therefore, it is essential to further understand how the 
tumor vasculature can be effectively targeted in order 
to develop new anti-angiogenic therapies. However, the 
knowledge about intracellular processes that mediate 
neovascularization is still limited. 
Here, we show that endothelial Cdk5 contributes 
to blood vessel development and tumor angiogenesis. 
In doing so, this work provides the irst evidence for an 
in vivo role of Cdk5 in blood vessel formation. There have 
been various reports including ours, describing functions 
of Cdk5 in endothelial cells: in detail, endothelial 
Cdk5 was implicated in endothelial senescence [47], in 
neovascularization after ischemic stroke [48], and in 
Figure 4: Cdk5 does not regulate the Jagged1-induced activation of the Notch pathway. (A) Effect of Cdk5 siRNA on 
Jagged1-induced expression of Notch downstream target genes Hey1, Heyβ and NRARP in HUVECs is shown (One-Way ANOVA, Tukey, 
SEM, ns: not signiicant). n = γ. nt: non-targeting siRNA. (B) Effect of Cdk5 inhibition by roscovitine (10 µM, 48 h) on Jagged1-induced 
expression of Notch downstream target genes Hey1, Heyβ and NRARP is shown (One-Way ANOVA, Tukey, SEM, ns: not signiicant). n = γ.
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Figure 5: Cdk5 regulates NICD generation. (A) Immunoblots from HUVECs transfected with nt (non-targeting) and Cdk5 siRNA 
and plated onto PBS- or DLL4-coated dishes probed with anti-NICD, anti-Cdk5, and anti-actin antibodies are shown. n = γ. The bar graph 
displays the quantiication of the NICD immunoblot normed to the loading control (One Way ANOVA, Tukey, SEM, *p ≤ 0.05). (B) 
Immunoblots from HUVECs untreated (co) or treated with roscovitine (rosco, 10 µM), plated onto PBS- or Dll4-coated dishes and probed 
with anti-NICD and anti-actin antibodies are shown. n = γ. The bar graph displays the quantiication of the NICD immunoblot normed 
to the loading control (One Way ANOVA, Tukey, SEM, *p ≤ 0.05). (C) Expression of Notch1 receptor mRNA of HUVECs transfected 
with nt (non-targeting) or Cdk5 siRNA is shown. One-Way ANOVA, Tukey, n = γ. (D) Immunoblots from HUVECs transfected with nt 
(non-targeting) or Cdk5 siRNA and probed with anti-Notch, anti-Cdk5, and anti-tubulin antibodies are shown. n = γ. (E) Immunoblots 
of HUVECs silenced with nt (non-targeting) or Cdk5 siRNA and treated with MG1γβ for β4 h before plating onto Dll4 and probed with 
anti-NICD, anti-Cdk5 and anti-actin antibodies are shown. n = γ. The bar graph displays the quantiication of the NICD immunoblot 
normed to the loading control (One Way ANOVA, Tukey, SEM, *p ≤ 0.05). (F) Immunoblots of HUVECs treated with MG1γβ for the 
indicated timepoints and probed with anti-ȕ-catenin and anti-actin antibodies are shown. n = β. The bar graph displays the quantiication of 
the NICD immunoblot normed to the loading control (One Way ANOVA, Tukey, SEM, ns: not signiicant). (G) Immunoblots of HUVECs 
overexpressing NICD or empty vector treated with/without roscovitine for the indicated times and probed with anti-NICD and anti-tubulin 
antibodies are shown. n = γ. (H) Immunoblots of HUVECs transfected with nt (non-targeting) or Cdk5 siRNA plated onto Dll4 and probed 
with anti-presenilin, anti-Cdk5, and anti-actin antibodies are shown. Phosphorylated and total presenilin is denoted by the upper and lower 
band and marked by arrows. n = γ. (I) Immunoblots of HUVECs treated with/without roscovitine at indicated concentrations plated onto 
Dll4 and probed with anti-presenilin and anti-actin antibodies are shown. Phosphorylated and total presenilin is denoted by the upper and 
lower band and marked by arrows. n = γ.
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diseases associated with NO dysfunction [49, 50]. Our 
former studies demonstrated that small molecule Cdk5 
inhibitors exert anti-angiogenic effects and that Cdk5 is 
implicated in endothelial cell migration by regulating the 
small GTPase Rac1 which was restricted to in vitro assays. 
However, the speciic in vivo role of Cdk5 in the blood 
vessel endothelium by genetic knockdown models has not 
been addressed to date. Of note, as we started to analyze 
the in vivo function of Cdk5 in the endothelium, we 
observed no changes in arterial-venous cell speciication 
and blood vessel morphology by Cdk5 knockdown in the 
endothelium [γγ]. In fact, we found that Cdk5 is essential 
for lymphatic vessel development and valve formation by 
phosphorylating the transcription factor Foxcβ [γγ]. Our 
present study though elucidates a crucial role of Cdk5 in 
blood vessel patterning.
With respect to the mechanisms and potential 
targets of Cdk5 action in blood vessels, rather the Dll4/
Figure 6: Cdk5 regulates Notch pathway dependent endothelial functions. (A) Proliferation of HUVECs transfected with nt 
(non-targeting) or Cdk5 siRNA and plated onto PBS or Dll4 is shown. One-Way ANOVA, Tukey, SEM *p ≤ 0.05. n = 4. (B) Spheroids 
generated from HUVECs transfected with nt (non-targeting) or Cdk5 siRNA embedded into Dll4 containing gels are shown. Quantiications 
of sprout length and number of sprouts are displayed. T-test, SEM, *p ≤ 0.001. Number of evaluated spheroids: non-targeting siRNA n = β1, 
Cdk5 siRNA n = β6. (C) Immunostainings of spheroids generated from nt (non-targeting) or Cdk5 siRNA transfected HUVECs for NICD 
(green) and Hoechst γγγ4β (blue) are shown. Scale bar 100 µm. n = γ.
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Figure 7: Cdk5 inhibition reduces tumor growth. (A) U87 tumors from mice treated with solvent (co) or roscovitine (rosco) is 
shown. n = 5. The graph shows tumor growth over time. Growth rate α of tumors is indicated (*p = γ × 10–7). (B) B16F1 tumors from 
Cdk5l/lVECCre mice treated with solvent (co) or roscovitine (rosco) is shown. The bar graph shows tumor growth over time (t-test, 
ns: not signiicant, n = γ). Staining of tumors Cdk5l/lVECCre mice for Ki67 (red, upper panel) and CDγ1 (red, lower panel) is shown 
(n = β). The bar graphs display respective quantiications. (C) Pharmakokinetics of Roscovitine in mice is shown. The graph displays the 
concentration (µg per 100 µl) of Roscovitine in blood of mice after i.p. injection at the indicated timepoints. n = γ mice per timepoint.
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Notch system was indicated to be important, as suggested 
by the reminiscent phenotype of Cdk5 knockout mice to 
angiogenesis observed by Dll4/Notch blockade. Similar 
to the genetic or pharmacologic inhibition of endothelial 
Cdk5, the disruption of Dll4/Notch signaling results 
in increased vessel sprouting during development [γ]. 
Dll4/Notch signaling regulates tip and stalk cell 
speciication during vascular morphogenesis. Dll4 is 
induced in endothelial tip cells and activates Notch in 
adjacent stalk cells which represses the tip cell phenotype. 
Inhibition of the Notch pathway results in increased 
vessel sprouting and branching due to excessive tip cell 
formation and endothelial cell proliferation. Moreover, in 
line with our results showing dysfunction of tumor vessels 
in endothelial Cdk5 knockout mice, preclinical models 
have demonstrated that blockade of Dll4/Notch signaling 
results in increased vessel sprouting and branching in 
tumors and impairs tumor growth by promoting non-
productive angiogenesis [6, 7]. With respect to the 
target of Cdk5 within the Dll4/Notch signaling hub our 
work points to an alteration of presenilin/Ȗ-secretase and 
therefore the regulation of NICD generation by endothelial 
Cdk5. In neurons presenilin/ Ȗ-secretase was identiied as 
Cdk5 target before [51]. Presenilin comprises the catalytic 
component of the Ȗ-secretase multiprotein complex that 
is essential for Notch receptor processing and NICD 
generation [γ5].
Therapeutic targeting of the Dll4/Notch pathway 
has evolved as an attractive anti-angiogenic strategy as the 
adaptive ability of neoplastic cells to become anti-VEGF 
resistant has arisen as a major obstacle to anti-angiogenic 
therapies [β] and can be caused by compensation of 
alternative angiogenesis mechanisms such as the Dll4/
Notch pathway [5, 8, 9]. Potentiated Notch signaling 
due to either loss of a negative regulator or increased 
expression of the Notch activating ligand Dll4 in the tumor 
vasculature correlates with tumorigenesis and therapeutic 
resistance [4, 5, 10, 5β, 5γ]. In breast cancer, high Dll4 
expression by intratumoral endothelial cells was elucidated 
as an adverse prognostic factor of patient survival [54]. 
In line, strong expression of Dll4 in ovarian cancer was 
associated with poor patient prognosis whereas low Dll4 
expression correlated with responsiveness to anti-VEGF 
therapy [8]. Recently, it was shown that the modulation 
of Dll4/Notch by the extracellular matrix (ECM) 
protein ibulin-γ promotes angiogenesis in high-grade 
gliomas [4β]. However, whereas Dll4 expression in tumors 
consistently affected the vascular phenotype, tumor 
growth was increased only in some tumors, probably 
due to differences in the vasculature and/or levels of 
endogenous components of the Dll4/Notch pathway 
[4, 6]. In line, our study shows that Cdk5 inhibition alone 
inhibited B16F1 melanoma growth but not LLC tumor 
growth. Importantly, Dll4/Notch blockade has been shown 
to inhibit the growth of anti-VEGF resistant tumors and 
even enhance the sensitivity of tumors to anti-VEGF 
treatment [5, 8, 9]. Consequently, various approaches have 
been developed to target the Dll4/Notch pathway including 
Figure 8: Cdk5 inhibition sensitizes to anti-angiogenic treatment. LLC tumors from control (co) or Cdk5l/lVECCre mice treated 
with solvent or the anti-VEGF antibody Bβ0–4.1.1 are shown. Quantiication of tumor weight is indicated. ANOVA on Ranks, Dunn’s 
Method, SEM, *p ≤ 0.05. control/solvent n = 10, control/anti-VEGF n = 9, Cdk5l/lVECCre/solvent n = 9, Cdk5l/lVECCre/anti-VEGF n = 8.
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anti-Dll4 antibodies, Dll4-Fc and Notch-Fc decoys, DNA 
vaccination, anti-Notch antibodies, as well as Ȗ-secretase 
inhibitors and anti-Dll4/Notch therapy is currently 
evaluated in clinical trials for cancer therapy [9]. Still, 
the molecular basis of this sensitizing effect has not been 
well explained [9]. Here we show that Cdk5 inhibition 
within the neovascular endothelium of burgeoning tumors 
can sensitize them for more effective anti-angiogenic 
treatment. This may be of particular relevance to tumors 
such as lewis lung carcinoma (LLC) which have been 
described to be resistant to anti-angiogenic treatment 
[4γ]. Thus, the control of Notch signaling by Cdk5 in the 
neovascularizing endothelium is proposed as an additional 
target for tumor treatment although up to now, absolutely 
selective inhibition speciically of Cdk5 is not possible 
as the currently available Cdk5 inhibitors interfere with 
other Cdks like Cdk1, Cdkβ, Cdk7, and Cdk9 as well. 
Nevertheless, inhibition by small molecules inhibiting 
Cdk5 and additionally Cdk1, Cdkβ, Cdk7, and Cdk9 have 
shown promising effects in cancer/angiogenesis [18, γ0, 
γ1, 55, 56]. In fact, as inhibition of several kinases can 
address different functions in endothelial as well as in 
tumor cells, and therefore interfere with tumor growth and 
progression in a multifaceted mode of action, this might be 
beneicial in terms of therapeutic eficiency. 
In sum, the present study elucidates an essential 
in vivo role of Cdk5 in tumor angiogenesis suggesting 
Cdk5 inhibition as a novel approach for anti-angiogenic 
treatment. 
MATERIALS AND METHODS
Animal experiments
All animal experiments were performed with 
approval by the District Government of Upper Bavaria 
in accordance with the German animal welfare and 
institutional guidelines.
Endothelial-speciic Cdk5 knockout mice
Generation, breeding, and genotyping of endothelial-
speciic Cdk5 knockout mice was previously described 
[γγ]. Floxed Cdk5 mice were described [57]. TieβCre mice 
were from Jackson Laboratory (B6.Cg-Tg(Tek-cre)1βFlv/J, 
0041β8). Tamoxifen-inducible Cdh5(PAC)-CreERTβ 
mice were described [γ4]. Endothelial Cdk5 knockdown 
in pups was achieved by tamoxifen injection at day 
1 – day γ (50 µg / day i.p., Sigma Aldrich). Cdk5 knockdown 
was proved at day 6 (Supplementary Figure 1A). 
For deletion of Cdk5 in adult mice, tamoxifen (0.5 mg/day 
i.p.) was injected at 5 consecutive days. Cdk5 knockdown 
was proved two weeks and four weeks after treatment with 
tamoxifen (Supplementary Figure 1B).
Tumor models
B16F1 melanoma cells (1 × 106 cells in 100 µl PBS) 
were subcutaneously injected into the lanks of 8 week old 
Cdk5l/lVECCre and control mice at day 15 after tamoxifen 
injection when Cdk5 was downregulated. Tumor growth 
was observed for 14 days (until dγ0). Tumor volume was 
evaluated every βnd day (π/6 × l × w × h). Tumor weight 
was evaluated. In case of therapy with roscovitine, mice 
were intraperitoneally treated with roscovitine (150 mg/kg, 
γ × per week) starting from day 7 after tumor cell 
injection, when tumors had established. The tumor volume 
was evaluated three times per week. Mice were sacriiced 
at day 14 and the tumor weight was determined.
U87 glioblastoma cells [4, 5] were subcutaneously 
injected (5 × 106 cells in 100 µl PBS:Matrigel 1:1) into the 
lanks of 6 week old female Balb/c nude mice (Harlan). 
Mice were treated intraperitoneally (i.p.) with roscovitine 
(150 mg/kg, γ × per week) starting at day 7 after tumor 
cell implantation when tumors had established and the 
tumor volume was evaluated twice per week. Mice were 
sacriiced at day 4β. Tumor volume was modelled using 
an exponential growth model where the tumor volume at 
a given time t (N(t)) is a function of the starting volume 
N (0), the time of growth t and of a growth rate α: 
N (t) = N (0) • expα • t. Modeling was performed using 
non-linear mixed effects modeling with the software 
NONMEM 7.γ. [58].
LLC cells (β × 106 cells in 100 µl PBS) cells were 
subcutaneously injected into the lanks of 8 week old 
Cdk5l/lVECCre and control mice at day 15 after tamoxifen 
injection when Cdk5 was downregulated. Starting at dγ 
after tumor cell implantation, mice were treated with 
anti-VEGF antibody (Bβ0–4.1.1, Genentech, 5 mg/kg 
β × / week, i.p.) or solvent (PBS) respectively. Mice were 
sacriiced at day 18 and tumor weight was evaluated.
Pharmacokinetics
Plasma concentrations of roscovitine were 
determined by HPLC-DAD. Mice were treated with 
roscovitine and blood was collected after 10, β0, γ0, 60, 
1β0, and β40 min. For each time point, blood of three mice 
was pooled. 
100 µl mice blood were mixed with β00 µl 
acetonitrile, vortexed (1 min), centrifuged (5 min, 10,000 
g, RT) and the supernatant was analyzed by HPLC-DAD 
using an Agilent Series 1100 HPLC system (Waldbronn, 
Germany) consisting of a quaternary pump system (G1γ11 
A QuatPump), an autosampler (G1γβ9 A ALS), a column 
oven (G1γ16 A ColComp) and a UV-DAD detector 
(G1γ15 A DAD). Chromatographic separation was carried 
out with an Agilent poroshell 1β0 EC-C18 (100 × γ.0 mm, 
i.d. β.7 µm) column (Waldbronn, Germany) and a mobile 
phase of acetonitrile and water (0.1% phosphoric acid, 
1.0% tetrahydrofuran) 15:85 (v/v). The total run time was 
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7 min with an isocratic low rate at 1.0 ml/min, and an 
injection volume of 10 µl. The column oven was set at 
50°C. The UV detection wave-length was set at β9β nm. 
Data analysis and instrument control was carried out 
with Agilent ChemStation® software Rev. B04.0β. The 
average retention time of roscovitine was γ.1 min. The 
concentration of roscovitine was determined according to 
an external standard calibration.
Retina preparation and staining
Retina preparation and staining was performed 
according to Pitulescu et al. [59]. Briely, eyes were 
removed, ixed in PFA 4% (β h, RT) and retinae were 
prepared. After blocking (β h, RT), retinae were stained for 
isolectin B4 (IB4, Alexa 488 conjugated, Millipore), and 
BrdU staining was performed. Nuclei were labeled with 
Hoechstγγγ4β. Pictures were taken with a Zeiss LSM 510 
META confocal microscope. The area covered by ECs, 
the numbers of branch points per ield, number of BrdU 
positive cells per ield, and of sprouts per 1,000 µm vessel 
length were calculated by using Image J.
Immunohistochemistry 
Parafin sections: Tumors were removed, ixed with 
PFA 4% for β4 h, left in PFA 1%, embedded into parafin 
and sections (5 µm) were prepared. 
Cryosections: Tumors were removed and frozen into 
TissueTek. 10 µm sections were prepared and ixed with 
formalin 4% (10 min, RT).
Stainings: Sections were blocked (1% BSA/PBS), 
incubated with primary antibodies (CDγ1, 55γγ70, BD 
Pharmingen; endomucin, sc-65495 Santa Cruz; α-SMA 
C6198, Sigma) for β h, at RT or o/n at 4°C, washed, 
incubated with AlexaFluor-labeled secondary antibodies 
(45 min, RT, Life Technologies) and Hoechst γγγ4β 
(5 µg/ml) and mounted (Fluorsave Reagent, Calbiochem). 
Pictures were taken with a Zeiss LSM 510 META confocal 
microscope. 
For evaluations of stainings, ImageJ and the particle 
counter plugin were used. Vessel number was determined 
by counting the number of vessels per mm2. Vessel 
size was determined by evaluating the area covered by 
vessels divided by the number of vessels per µm2. For the 
quantiication of smooth muscle cell coverage of vessels, 
tumor sections were stained for CDγ1 and α-smooth 
muscle cell actin (α-SMA). Vessels with and without 
αSMA-staining were counted.
Whole mount staining of embryonic skin and 
yolk sacs
Tissues were removed, ixed (formalin 4%, 
γ0 min, RT), washed, blocked (1 h, RT, 0.5% TritonX, β% 
BSA/PBS), incubated with anti-CDγ1 primary antibodies 
(55γγ70, BD Pharmingen) (o/n, 4°C), washed, incubated 
with AlexaFluor-labeled secondary antibodies (β h, RT), 
and mounted. Numbers of branch points per ield were 
calculated by using Image J and the particle counter plugin.
Tumor vessel perfusion 
At day 15 after tumor cell inoculation, mice were 
intravenously injected (tail vein) with FITC-Lectin 
(150 µg, 1 mg/ml, Sigma Aldrich). After circulation of 
FITC-Lectin for 5 min, mice were sacriiced and tumors 
were removed. Staining was performed according to the 
description under immunohistochemistry. Vessels with 
and without FITC-Lectin labeling were counted by using 
ImageJ and the particle counter plugin.
Cells 
HUVECs were cultivated as described [γβ] with 
Endothelial Cell Growth Medium (ECGM, Promocell) 
containing 10% FCS. Embryonic blood vessel endothelial 
cells (BECs) and liver sinusoidal endothelial cells 
LSECs were isolated and cultivated as described [γγ]. 
For experiments with Dll4, plates were coated with Dll4 
(5 µg/ml; 1 h RT or o/n 4°C; human Dll4 for HUVECs 
and mouse Dll4 for mouse BECs, both R & D Systems 
1506-D4 and 1γ89-D4). Plates were washed once with 
PBS before cells were plated. For proteasome inhibition 
experiments, MG1γβ (1 µM, Enzo Life Sciences) 
stimulation was started 1 h before re-plating of HUVECs 
onto Dll4. HUVECs were plated onto Dll4 for 1 h or β4 h. 
BECs were plated onto Dll4 for β4 h.
For experiments with Jagged1, plates were coated 
with Jagged1 (10 µg/ml; 1 h RT; R & D Systems 1β77-JG). 
Plates were washed once with PBS before cells were 
plated. HUVECs were treated with roscovitine (10 µM) 
or nt (non-targeting) or Cdk5 siRNA and plated onto Dll4 
for 48 h. 
Transfection of cells
HUVECs were transfected using Targefect 
(Targeting Systems; El Cajon, California) according to 
the manufacturer’s protocol. DNA, Transfection Media, 
Targefect and Virofect Enhancer were mixed and incubated 
for β5 min. The transfection complex was added to the 
cells for β h. Fresh HUVEC medium was added to the 
cells for β4 h. NICD plasmid was from addgene (β689β). 
The siRNAs were from Thermo Scientiic/Dharmacon: 
nt siRNA D-001810–01; Cdk5 siRNA J-00γβγ9–09 and 
J-00γβγ9–10. For the experiments involving Cdk5 siRNA, 
a mix of both siRNAs was used.
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Proliferation
HUVECs were transfected with nt or Cdk5 siRNA 
(Thermo Scientiic). β4 h after transfection, cells (1500 
cells per 96-well) were seeded onto PBS or Dll4 coated 
plates. Initial cell number was determined after 1 h. 
Proliferation was measured after 7β h via crystal violet 
staining.
Spheroids
HUVECs were transfected with nt or Cdk5 siRNA. 
Spheroids were generated via the hanging drop method 
as described [γ7]. Briely, a suspension of HUVECs and 
β0% Methocel was mixed and β0 µl drops were seeded 
onto a petri dish and incubated upside down over night. 
Spheroids were embedded into HUVEC growth medium 
containing 5% Minimal Essential Eagle’s Medium 
(Sigma), 5% Bicarbonate, 60% collagen and Dll4 
(5 µg/ml). The collagen pellets were covered with ECGM 
containing β0% FCS. Pictures were taken on day 0, 
1, β and γ. Sprout length and number of sprouts were 
determined.
For spheroid staining, embedded spheroids were 
ixed with 4% PFA, permeabilized with 0, β% Triton X 
and blocked with 1% BSA in PBS for γ days. Primary 
antibody (NICD 4147, Cell Signalling) was incubated 
for γ days and secondary antibody (AlexaFluor 488, Life 
Technologies) for further γ days. Nuclei were stained with 
Hoechst γγγ4β (0, 5 µg/ml, 40 min, RT). Pictures were 
taken at the Leica SP8 SMD confocal microscope.
Immunoblotting 
Immunoblotting was described previously [γγ]. The 
following primary antibodies were used: actin (MAB 150 
1R, Chemicon), Cdk5 (AHZ049β, Life Technologies), 
NICD (4147 Cell Signalling), presenilin (564γ, Cell 
Signaling).
RT-PCR
mRNA was isolated using the Qiagen RNeasy Mini 
Kit. For reverse transcription the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) was used. 
RT-PCR was performed with the 7γ00 Real Time PCR 
System. The following Taqman gene expression assays 
were used: Cdk5 Hs00γ58991_g1 and Mm011γ4945_
g1, Hey1 Hs00βγβ618_m1 and Mm00468865_m1, 
Heyβ Hs00βγβ6ββ_m1 and Mm00469β80_m1, NRARP 
Hs0110410β_s1 and Mm0048β5β9_s1, VE-cadherin 
Mm004869γ8_m1 (Applied Biosystems). GAPDH was 
used as housekeeper.
Statistics
All experiments were performed at least three times 
(biological replicates) Respective tests, p-values and 
exact numbers of independently performed experiments 
are indicated in the respective igure legends. Graph 
data represent means ± SEM. Statistical analysis was 
performed using SigmaStat Version γ.1.
ACKNOWLEDGMENTS
We thank Paul Greengard (Rockefeller University) 
for providing the loxed Cdk5 mice. We thank Adrian 
Harris (Oxford University Department of Oncology, 
Weatherall Institute of Molecular Medicine, John Radcliffe 
Hospital, Oxford) for providing U87 glioblastoma 
cells. We thank Genentech for providing the anti-VEGF 
antibody Bβ0–4.1.1. We thank Helene Maby-El Hajjami 
(University of Lausanne) for the LEC/BEC isolation 
protocol. We thank Kerstin Loske for mouse genotyping. 
The animal facility of the Department of Pharmacy, 
Ludwig-Maximilians-University Munich is gratefully 
acknowledged. This work was supported by German 
Research Foundation (ZA 186/4–1).
FUNDINGS
This work was supported by German Research 
Foundation (ZA 186/4–1). Siwei Zhang was supported by 
the LMU - China Scholarship Council.
CONFLICTS OF INTEREST
None.
REFERENCES
 1. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms 
of anti-tumour activity. Nat Rev Cancer. β008; 8:579–591.
 β. Bergers G, Hanahan D. Modes of resistance to 
anti-angiogenic therapy. Nat Rev Cancer. β008; 8:59β–60γ.
 γ. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, 
Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, 
Yoon K, Rossant J, Iruela-Arispe ML, et al. Dll4 signalling 
through Notch1 regulates formation of tip cells during 
angiogenesis. Nature. β007; 445:776–780.
 4. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, 
Biswas S, Turley H, Heikamp E, Hainfellner JA, Harris AL. 
Delta-like 4 Notch ligand regulates tumor angiogenesis, 
improves tumor vascular function, and promotes tumor 
growth in vivo. Cancer Res. β007; 67:11β44–11β5γ.
 5. Holopainen T, Bry M, Alitalo K, Saaristo A. Perspectives 
on lymphangiogenesis and angiogenesis in cancer. J Surg 
Oncol. β011; 10γ:484–488.
Oncotarget6102www.impactjournals.com/oncotarget
 6. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, 
Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G. 
Blockade of Dll4 inhibits tumour growth by promoting non-
productive angiogenesis. Nature. β006; 444:10γβ–10γ7.
 7. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, 
Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, 
Singh M, Chien M, Tan C, et al. Inhibition of Dll4 signalling 
inhibits tumour growth by deregulating angiogenesis. 
Nature. β006; 444:108γ–1087.
 8. Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, 
Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, 
Roh JW, Matsuo K, et al. Biological roles of the Delta 
family Notch ligand Dll4 in tumor and endothelial cells in 
ovarian cancer. Cancer Res. β011; 71:60γ0–60γ9.
 9. Kuhnert F, Kirshner JR, Thurston G. Dll4-Notch signaling 
as a therapeutic target in tumor angiogenesis. Vasc Cell. 
β011; γ:β0.
10. Ranganathan P, Weaver KL, Capobianco AJ. Notch 
signalling in solid tumours: a little bit of everything but not 
all the time. Nat Rev Cancer. β011; 11:γγ8–γ51.
11. Dhavan R, Tsai LH. A decade of CDK5. Nat Rev Mol Cell 
Biol. β001; β:749–759.
1β. Barnett DG, Bibb JA. The role of Cdk5 in cognition and 
neuropsychiatric and neurological pathology. Brain Res 
Bull. β011; 85:9–1γ.
1γ. Cheung ZH, Ip NY. Cdk5: a multifaceted kinase in 
neurodegenerative diseases. Trends Cell Biol. β01β; 
ββ:169–175.
14. Liebl J, Furst R, Vollmar AM, Zahler S. Twice switched at 
birth: cell cycle-independent roles of the “neuron-speciic” 
cyclin-dependent kinase 5 (Cdk5) in non-neuronal cells. 
Cell Signal. β011; βγ:1698–1707.
15. Contreras-Vallejos E, Utreras E, Gonzalez-Billault C. Going 
out of the brain: non-nervous system physiological and 
pathological functions of Cdk5. Cell Signal. β01β; β4:44–5β.
16. Rosales JL, Lee KY. Extraneuronal roles of cyclin-
dependent kinase 5. Bioessays. β006; β8:10βγ–10γ4.
17. Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, 
Ball DW, Goggins M, Maitra A, Nelkin BD. Inhibiting the 
cyclin-dependent kinase CDK5 blocks pancreatic cancer 
formation and progression through the suppression of 
Ras-Ral signaling. Cancer Res. β010; 70:4460–4469.
18. Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-
Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, 
Fendrich V, Rajeshkumar NV, Matsui W, Brossart P, et al. 
Cyclin-dependent kinase inhibitor Dinaciclib (SCH7β7965) 
inhibits pancreatic cancer growth and progression in murine 
xenograft models. Cancer Biol Ther. β011; 1β:598–609.
19. Eggers JP, Grandgenett PM, Collisson EC, Lewallen ME, 
Tremayne J, Singh PK, Swanson BJ, Andersen JM, 
Caffrey TC, High RR, Ouellette M, Hollingsworth MA. 
Cyclin-dependent kinase 5 is ampliied and overexpressed 
in pancreatic cancer and activated by mutant K-Ras. Clin 
Cancer Res. β011; 17:6140–6150.
β0. Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, 
Ball DW, Nelkin BD. Cyclin-dependent kinase 5 activity 
controls cell motility and metastatic potential of prostate 
cancer cells. Cancer Res. β006; 66:7509–7515.
β1. Jin JK, Tien PC, Cheng CJ, Song JH, Huang C, Lin SH, 
Gallick GE. Talin1 phosphorylation activates beta1 
integrins: a novel mechanism to promote prostate cancer 
bone metastasis. Oncogene. β015; γ4:1811–β1.
ββ. Pozo K, Castro-Rivera E, Tan C, Plattner F, Schwach G, 
Siegl V, Meyer D, Guo A, Gundara J, Mettlach G, Richer E, 
Guevara JA, Ning L, et al. The role of Cdk5 in neuroendocrine 
thyroid cancer. Cancer Cell. β01γ; β4:499–511.
βγ. Pozo K, Hillmann A, Augustyn A, Plattner F, Hai T, Singh T, 
Ramezani S, Sun X, Pfragner R, Minna JD, Cote GJ, Chen H, 
Bibb JA, et al. Differential expression of cell cycle 
regulators in CDK5-dependent medullary thyroid carcinoma 
tumorigenesis. Oncotarget. β015; 6:1β080–1β09γ. doi: 
10.186γβ/oncotarget.γ81γ.
β4. Liu R, Tian B, Gearing M, Hunter S, Ye K, Mao Z. Cdk5-
mediated regulation of the PIKE-A-Akt pathway and 
glioblastoma cell invasion. Proc Natl Acad Sci U S A. β008; 
105:7570–7575.
β5. Xie W, Wang H, He Y, Li D, Gong L, Zhang Y. CDK5 
and its activator Pγ5 in normal pituitary and in pituitary 
adenomas: relationship to VEGF expression. International 
journal of biological sciences. β014; 10:19β–199.
β6. Liang Q, Li L, Zhang J, Lei Y, Wang L, Liu DX, Feng J, 
Hou P, Yao R, Zhang Y, Huang B, Lu J. CDK5 is essential 
for TGF-beta1-induced epithelial-mesenchymal transition 
and breast cancer progression. Sci Rep. β01γ; γ:β9γβ.
β7. Demelash A, Rudrabhatla P, Pant HC, Wang X, Amin ND, 
McWhite CD, Naizhen X, Linnoila RI. Achaete-scute 
homologue-1 (ASH1) stimulates migration of lung cancer 
cells through Cdk5/pγ5 pathway. Mol Biol Cell. β01β; 
βγ:β856–β866.
β8. Chen XX, Xie FF, Zhu XJ, Lin F, Pan SS, Gong LH, Qiu JG, 
Zhang WJ, Jiang QW, Mei XL, Xue YQ, Qin WM, Shi Z, 
et al. Cyclin-dependent kinase inhibitor dinaciclib 
potently synergizes with cisplatin in preclinical models 
of ovarian cancer. Oncotarget. β015. doi: 10.186γβ/
oncotarget.γ717.
β9. Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De Toni EN, Mayr D, 
Brandl L, Kirchner T, Zahler S, Gerbes AL, Vollmar AM. 
Targeting cyclin dependent kinase 5 in hepatocellular 
carcinoma - A novel therapeutic approach. J Hepatol. β015; 
6γ:10β–1γ.
γ0. Liebl J, Krystof V, Vereb G, Takacs L, Strnad M, Pechan P, 
Havlicek L, Zatloukal M, Furst R, Vollmar AM, Zahler S. 
Anti-angiogenic effects of purine inhibitors of cyclin 
dependent kinases. Angiogenesis. β011; 14:β81–β91.
γ1. Weitensteiner SB, Liebl J, Krystof V, Havlicek L, Gucky T, 
Strnad M, Furst R, Vollmar AM, Zahler S. Trisubstituted 
pyrazolopyrimidines as novel angiogenesis inhibitors. PLoS 
One. β01γ; 8:e54607.
Oncotarget6103www.impactjournals.com/oncotarget
γβ. Liebl J, Weitensteiner SB, Vereb G, Takacs L, Furst R, 
Vollmar AM, Zahler S. Cyclin-dependent kinase 5 regulates 
endothelial cell migration and angiogenesis. J Biol Chem. 
β010; β85:γ59γβ–γ594γ.
γγ. Liebl J, Zhang S, Moser M, Agalarov Y, Demir CS, Hager B, 
Bibb JA, Adams RH, Kiefer F, Miura N, Petrova TV, 
Vollmar AM, Zahler S. Cdk5 controls lymphatic vessel 
development and function by phosphorylation of Foxcβ. 
Nat Commun. β015; 6:7β74.
γ4. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, 
Bochenek ML, Sakakibara A, Adams S, Davy A, Deutsch U, 
Luthi U, Barberis A, Benjamin LE, Makinen T, et al. 
Ephrin-Bβ controls VEGF-induced angiogenesis and 
lymphangiogenesis. Nature. β010; 465:48γ–486.
γ5. Kopan R, Ilagan MX. The canonical Notch signaling 
pathway: unfolding the activation mechanism. Cell. β009; 
1γ7:β16–βγγ.
γ6. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. 
beta-catenin is a target for the ubiquitin-proteasome 
pathway. EMBO J. 1997; 16:γ797–γ804.
γ7. Guarani V, Delorian G, Franco CA, Kruger M, Phng LK, 
Bentley K, Toussaint L, Dequiedt F, Mostoslavsky R, 
Schmidt MH, Zimmermann B, Brandes RP, Mione M, 
et al. Acetylation-dependent regulation of endothelial 
Notch signalling by the SIRT1 deacetylase. Nature. β011; 
47γ:βγ4–βγ8.
γ8. Benedito R, Roca C, Sorensen I, Adams S, Gossler A, 
Fruttiger M, Adams RH. The notch ligands Dll4 and 
Jagged1 have opposing effects on angiogenesis. Cell. β009; 
1γ7:11β4–11γ5.
γ9. Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, 
Baratte B, Koken M, Coburn SP, Tang L, Jiang T, Liang DC, 
Galons H, Dierick JF, et al. Roscovitine targets, protein 
kinases and pyridoxal kinase. J Biol Chem. β005; 
β80:γ1β08–γ1β19.
40. Gray N, Detivaud L, Doerig C, Meijer L. ATP-site directed 
inhibitors of cyclin-dependent kinases. Current medicinal 
chemistry. 1999; 6:859–875.
41. Delehouze C, Godl K, Loaec N, Bruyere C, Desban N, Oumata 
N, Galons H, Roumeliotis TI, Giannopoulou EG, Grenet J, 
Twitchell D, Lahti J, Mouchet N, et al. CDK/CK1 inhibitors 
roscovitine and CR8 downregulate ampliied MYCN in 
neuroblastoma cells. Oncogene. β014; γγ:5675–5687.
4β. Nandhu MS, Hu B, Cole SE, Erdreich-Epstein A, 
Rodriguez-Gil DJ, Viapiano MS. Novel paracrine 
modulation of Notch-DLL4 signaling by ibulin-γ promotes 
angiogenesis in high-grade gliomas. Cancer Res. β014; 
74:54γ5–5448.
4γ. Bais C, Wu X, Yao J, Yang S, Crawford Y, McCutcheon K, 
Tan C, Kolumam G, Vernes JM, Eastham-Anderson J, 
Haughney P, Kowanetz M, Hagenbeek T, et al. PlGF 
blockade does not inhibit angiogenesis during primary 
tumor growth. Cell. β010; 141:166–177.
44. Levitzki A. Tyrosine kinase inhibitors: views of selectivity, 
sensitivity, and clinical performance. Annu Rev Pharmacol 
Toxicol. β01γ; 5γ:161–185.
45. Adams RH, Alitalo K. Molecular regulation of angiogenesis 
and lymphangiogenesis. Nat Rev Mol Cell Biol. β007; 8:464–
478.
46. Gacche RN, Meshram RJ. Angiogenic factors as potential 
drug target: eficacy and limitations of anti-angiogenic 
therapy. Biochimica et biophysica acta. β014; 1846:161–179.
47. Bai B, Liang Y, Xu C, Lee MY, Xu A, Wu D, Vanhoutte PM, 
Wang Y. Cyclin-dependent kinase 5-mediated 
hyperphosphorylation of sirtuin-1 contributes to the 
development of endothelial senescence and atherosclerosis. 
Circulation. β01β; 1β6:7β9–740.
48. Slevin M, Krupinski J. Cyclin-dependent kinase-5 targeting 
for ischaemic stroke. Curr Opin Pharmacol. β009; 9:119–1β4.
49. Cho DH, Seo J, Park JH, Jo C, Choi YJ, Soh JW, Jo I. Cyclin-
dependent kinase 5 phosphorylates endothelial nitric oxide 
synthase at serine 116. Hypertension. β010; 55:γ45–γ5β.
50. Lee CH, Wei YW, Huang YT, Lin YT, Lee YC, Lee KH, Lu PJ. 
CDK5 phosphorylates eNOS at Ser-11γ and regulates NO 
production. J Cell Biochem. β010; 110:11β–117.
51. Lau KF, Howlett DR, Kesavapany S, Standen CL, Dingwall C, 
McLoughlin DM, Miller CC. Cyclin-dependent kinase-5/
pγ5 phosphorylates Presenilin 1 to regulate carboxy-terminal 
fragment stability. Mol Cell Neurosci. β00β; β0:1γ–β0.
5β. Kang M, Jiang B, Xu B, Lu W, Guo Q, Xie Q, Zhang B, 
Dong X, Chen D, Wu Y. Delta like ligand 4 induces impaired 
chemo-drug delivery and enhanced chemoresistance in 
pancreatic cancer. Cancer Lett. β01γ; γγ0:11–β1.
5γ. Jubb AM, Browning L, Campo L, Turley H, Steers G, 
Thurston G, Harris AL, Ansorge O. Expression of vascular 
Notch ligands Delta-like 4 and Jagged-1 in glioblastoma. 
Histopathology. β01β; 60:740–747.
54. Jubb AM, Soilleux EJ, Turley H, Steers G, Parker A, Low I, 
Blades J, Li JL, Allen P, Leek R, Noguera-Troise I, Gatter KC, 
Thurston G, et al. Expression of vascular notch ligand 
delta-like 4 and inlammatory markers in breast cancer. Am 
J Pathol. β010; 176:β019–β0β8.
55. Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, 
Bruins LA, Keats JJ, Braggio E, Sereduk C, Mousses S, 
Stewart AK. RNAi screen of the druggable genome 
identiies modulators of proteasome inhibitor sensitivity in 
myeloma including CDK5. Blood. β011; 117:γ847–γ857.
56. Haider C, Grubinger M, Reznickova E, Weiss TS, 
Rotheneder H, Miklos W, Berger W, Jorda R, Zatloukal M, 
Gucky T, Strnad M, Krystof V, Mikulits W. Novel inhibitors 
of cyclin-dependent kinases combat hepatocellular 
carcinoma without inducing chemoresistance. Mol Cancer 
Ther. β01γ; 1β:1947–1957.
57. Hawasli AH, Benavides DR, Nguyen C, Kansy JW, 
Hayashi K, Chambon P, Greengard P, Powell CM, Cooper DC, 
Bibb JA. Cyclin-dependent kinase 5 governs learning and 
Oncotarget6104www.impactjournals.com/oncotarget
synaptic plasticity via control of NMDAR degradation. Nat 
Neurosci. β007; 10:880–886.
58. Beal S, Sheiner, L.B., Boeckmann, A., & Bauer, R.J. 
NONMEM User’s Guides. (1989–β009). Icon Development 
Solutions, Ellicott City, MD, USA,. β009.
59. Pitulescu ME, Schmidt I, Benedito R, Adams RH. Inducible 
gene targeting in the neonatal vasculature and analysis of 
retinal angiogenesis in mice. Nat Protoc. β010; 5:1518–15γ4.
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2016
Inhibition of endothelial Cdk5 reduces tumor growth by 
promoting non-productive angiogenesis
Supplementary Materials
Supplementary Figure S1: Cdk5 Knockdown in inducible Cdk5l/lVECCre mice. (A) Immunoblots and quantitative 
evaluation of liver sinusoidal endothelial cells (LSECs) of d6 pups with control and Cdk5l/lVECCre genotype that were injected with 
tamoxifen (50 µg / day i.p.) from day 1 to day 3 for Cdk5 and actin (loading control) is shown (B) Western blots and quantitative 
evaluations of liver sinusoidal endothelial cells (LSECs) of adult mice with control and Cdk5l/lVECCre genotype that were injected 
with tamoxifen (0.5 mg / day i.p.) for ive consecutive days two weeks and four weeks after tamoxifen injection for Cdk5 and actin 
(loading control) are shown.
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